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Abstract
Background: The Reporting Recommendations for
Tumor Marker Prognostic Studies (REMARK) checklist
consists of 20 items to report for published tumor
marker prognostic studies. It was developed to
address widespread deficiencies in the reporting of
such studies. In this paper we expand on the REMARK
checklist to enhance its use and effectiveness through
better understanding of the intent of each item and
why the information is important to report.
Methods: REMARK recommends including a
transparent and full description of research goals and
hypotheses, subject selection, specimen and assay
considerations, marker measurement methods,
statistical design and analysis, and study results. Each
checklist item is explained and accompanied by
published examples of good reporting, and relevant
empirical evidence of the quality of reporting. We
give prominence to discussion of the ‘REMARK profile’,
a suggested tabular format for summarizing key study
details.
Summary: The paper provides a comprehensive
overview to educate on good reporting and provide
a valuable reference for the many issues to consider
when designing, conducting, and analyzing tumor
marker studies and prognostic studies in medicine in
general.
To encourage dissemination of the Reporting
Recommendations for Tumor Marker Prognostic
Studies (REMARK): Explanation and Elaboration, this
article has also been published in PLoS Medicine.
Background
The purpose of this paper is to provide more complete
explanations of each of the Reporting Recommendations
for Tumor Marker Prognostic Studies (REMARK) check-
list items and to provide specific examples of good report-
ing drawn from the published literature. The initial
REMARK paper [1-7] recommended items that should be
reported in all published tumor marker prognostic studies
(Table 1). The recommendations were developed by a
committee initially convened under the auspices of the
National Cancer Institute and the European Organisation
for Research and Treatment of Cancer. They were based
on the rationale that more transparent and complete
reporting of studies would enable others to better judge
the usefulness of the data and to interpret the study results
in the appropriate context. Similar explanation and ela-
boration papers had been written to accompany other
reporting guidelines [8-11]. No changes to the REMARK
checklist items are being suggested here. We hope that the
current paper will serve an educational role and lead to
more effective implementation of the REMARK recom-
mendations, resulting in more consistent, high quality
reporting of tumor marker studies.
Our intent is to explain how to properly report prog-
nostic marker research, not to specify how to perform
the research. However, we believe that fundamental to an
appreciation of the importance of good reporting is a
basic understanding of how various factors such as speci-
men selection, marker assay methodology and statistical
study design and analysis can lead to different study
results and interpretations. Many authors have discussed
the fact that widespread methodological and reporting
deficiencies plague the prognostic literature in cancer
and other specialties [12-21]. Careful reporting of what
was done and what results were obtained allows for bet-
ter assessment of study quality and greater understanding
of the relevance of the study conclusions. When available,
we have cited published studies presenting empirical
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requested by the checklist items.
We recognize that tumor marker studies are generally
collaborative efforts among researchers from a variety of
disciplines. The current paper covers a wide range of
topics and readers representing different disciplines may
find certain parts of the paper more accessible than
other parts. Nonetheless, it is helpful if all involved have
a basic understanding of the collective obligations of the
study team.
We have attempted to minimize distractions from
more highly technical material by the use of boxes with
supplementary information. The boxes are intended to
help readers refresh their memories about some theore-
tical points or be quickly informed about technical back-
ground details. A full understanding of these points may
require studying the cited references.
We aimed to provide a comprehensive overview that not
only educates on good reporting but provides a valuable
reference for the many issues to consider when designing,
Table 1 The REMARK checklist [1-7]
INTRODUCTION
1 State the marker examined, the study objectives, and any pre-specified hypotheses.
MATERIALS AND METHODS
Patients
2 Describe the characteristics (for example, disease stage or co-morbidities) of the study patients, including their source and inclusion and
exclusion criteria.
3 Describe treatments received and how chosen (for example, randomized or rule-based).
Specimen characteristics
4 Describe type of biological material used (including control samples) and methods of preservation and storage.
Assay methods
5 Specify the assay method used and provide (or reference) a detailed protocol, including specific reagents or kits used, quality control
procedures, reproducibility assessments, quantitation methods, and scoring and reporting protocols. Specify whether and how assays were
performed blinded to the study endpoint.
Study design
6 State the method of case selection, including whether prospective or retrospective and whether stratification or matching (for example, by stage
of disease or age) was used. Specify the time period from which cases were taken, the end of the follow-up period, and the median follow-up
time.
7 Precisely define all clinical endpoints examined.
8 List all candidate variables initially examined or considered for inclusion in models.
9 Give rationale for sample size; if the study was designed to detect a specified effect size, give the target power and effect size.
Statistical analysis methods
10 Specify all statistical methods, including details of any variable selection procedures and other model-building issues, how model assumptions
were verified, and how missing data were handled.
11 Clarify how marker values were handled in the analyses; if relevant, describe methods used for cutpoint determination.
RESULTS
Data
12 Describe the flow of patients through the study, including the number of patients included in each stage of the analysis (a diagram may be
helpful) and reasons for dropout. Specifically, both overall and for each subgroup extensively examined report the number of patients and the
number of events.
13 Report distributions of basic demographic characteristics (at least age and sex), standard (disease-specific) prognostic variables, and tumor
marker, including numbers of missing values.
Analysis and presentation
14 Show the relation of the marker to standard prognostic variables.
15 Present univariable analyses showing the relation between the marker and outcome, with the estimated effect (for example, hazard ratio and
survival probability). Preferably provide similar analyses for all other variables being analyzed. For the effect of a tumor marker on a time-to-
event outcome, a Kaplan-Meier plot is recommended.
16 For key multivariable analyses, report estimated effects (for example, hazard ratio) with confidence intervals for the marker and, at least for the
final model, all other variables in the model.
17 Among reported results, provide estimated effects with confidence intervals from an analysis in which the marker and standard prognostic
variables are included, regardless of their statistical significance.
18 If done, report results of further investigations, such as checking assumptions, sensitivity analyses, and internal validation.
DISCUSSION
19 Interpret the results in the context of the pre-specified hypotheses and other relevant studies; include a discussion of limitations of the study.
20 Discuss implications for future research and clinical value.
we have changed ‘univariate’ to ‘univariable’ in item 15 for consistency with ‘multivariable’.
Altman et al. BMC Medicine 2012, 10:51
http://www.biomedcentral.com/1741-7015/10/51
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item is accompanied by one or more examples of good
reporting drawn from the published literature. We hope
that readers will find the paper useful not only when they
are reporting their studies but also when they are planning
their studies and analyzing their study data.
This paper is structured as the original checklist, accord-
ing to the typical sections of scientific reports: Introduc-
tion, Materials and Methods, Results and Discussion.
There are numerous instances of cross-referencing
between sections reflecting the fact that the sections are
inter-related, for example, one must speak about the
analysis methods used in order to discuss presentation
of results obtained using those methods. These cross-
references do not represent redundancies in the material
presented and readers are reminded that distinctions in
focus and emphasis between different items will some-
times be subtle.
One suggestion in the REMARK checklist is to include a
diagram showing the flow of patients through the study
(see Item 12). We elaborate upon that idea in the current
paper. The flow diagram is an important element of the
Consolidated Standards of Reporting Trials (CONSORT)
Statement, which was developed to improve reporting of
randomized controlled trials (RCTs) [8,22,23]. Many
papers reporting randomized trial results present a flow
diagram showing numbers of patients registered and
randomized, numbers of patients excluded or lost to fol-
low-up by treatment arms, and numbers analyzed. Flow
diagrams are also recommended in the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) Statement for reporting observational studies,
including cohort studies [9]. A diagram would indeed be
useful for prognostic studies to clarify the numbers and
characteristics of patients included at each stage of the
study. There are additional key aspects of prognostic
studies that need to be reported and would benefit from
standardized presentation. Accordingly we have developed
a ‘REMARK profile’ as a proposed format for describing
succinctly key aspects of the design and analysis of a prog-
nostic marker study; we discuss the profile in detail in
Item 12 below.
The original scope of the REMARK recommendations
focused on studies of prognostic tumor markers that
reported measurement of biological molecules found in
tissues, blood and other body fluids. The recommenda-
tions also apply more generally to prognostic factors other
than biological molecules that are often assessed in cancer
patients, including the size of the tumor, abnormal fea-
tures of the cells, the presence of tumor cells in regional
lymph nodes, age and gender among others. Prognostic
research includes study of the wide variety of indicators
that help clinicians predict the course of a patient’sd i s e a s e
in the context of standard care. REMARK generally applies
to any studies involving prognostic factors, whether those
prognostic factors are biological markers, imaging assess-
ments, clinical assessments or measures of functional sta-
tus in activities of daily living. REMARK applies to other
diseases in addition to cancer. The processes of measuring
and reporting the prognostic factors may differ, but the
same study reporting principles apply.
We suggest that most of the recommendations also
apply to studies looking at the usefulness of a marker for
the prediction of benefit from therapy (typically called a
predictive marker in oncology). Traditionally, predictive
markers are evaluated by determination of whether the
benefit of the treatment of interest compared to another
standard treatment depends on the marker status or
value. (See also Items 3 and 9 and Box 1 below.) A logical
corollary to such a finding is that the prognostic value of
that marker depends on the treatment the patient
Box 1. Subgroups and interactions: the analysis
of joint effects
It is often of interest to consider whether the effect
of a marker differs in relation to a baseline variable,
which may be categorical or continuous. Categorical
variables, such as stage of disease, naturally define
subgroups and continuous variables are often cate-
gorized by using one or more cutpoints. Investigating
whether the marker effect is different (modified) in
subgroups is popular. Epidemiologists speak about
effect modification; more generally this phenomenon
refers to the interaction between two variables.
In the context of randomized trials, one of these vari-
ables is the treatment and the other variable defines
subgroups of the population. Here the interaction
between treatment and the marker indicates whether
the marker is predictive of treatment effect (that is, a
p r e d i c t i v em a r k e r )[ 1 8 5 ] .T h i sa n a l y s i si se a s i e s tf o ra
binary marker. Subgroup analyses are often conducted.
The interpretation of their results depends critically on
whether the subgroup analyses were pre-specified or
conducted post hoc based on results seen in the data.
Subgroup differences are far more convincing when
such an effect had been postulated; unanticipated sig-
nificant effects are more likely to be chance findings
and should be interpreted as being interesting hypoth-
eses needing confirmation from similar trials. The
same principles apply to consideration of subgroups in
prognostic marker studies.
Subgroup analyses need to be done properly and
interpreted cautiously. It is common practice to calcu-
late separate P values for the prognostic effect of the
marker in separate subgroups, often followed by an
erroneous judgment that the marker has an effect in
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a special class of prognostic markers. Consequently,
REMARK items apply to many aspects of these studies.
In the explanations that follow for each of the checklist
items, we attempted to make note of some special con-
siderations for studies evaluating predictive markers. We
hope that authors who report predictive marker studies
will therefore find our recommendations useful. As pre-
dictive markers are usually evaluated in randomized
trials, CONSORT [11] will also apply to reporting of pre-
dictive marker studies.
Although REMARK was primarily aimed at the report-
ing of studies that have evaluated the prognostic value of a
single marker, the recommendations are substantially
relevant to studies investigating more than one marker,
including studies investigating complex markers that are
composed of a few to many components, such as multi-
variable classification functions or indices, or are based on
prognostic decision algorithms. These reporting recom-
mendations do not attempt to address reporting of all
aspects of the development or validation of these complex
markers, but several key elements of REMARK do also
apply to these developmental studies. Moreover, once
these complex markers are fully defined, their evaluation
in clinical studies is entirely within the scope of REMARK.
The development of prognostic markers generally
involves a series of studies. These begin with identification
of a relationship between a biological feature (for example,
proliferative index or genetic alteration) and a clinical
characteristic or outcome. To establish a clear and possibly
causal relationship, a series of studies are conducted to
address increasingly demanding hypotheses. The
REMARK recommendations attempt to recognize these
stages of development. For example, the discussion of
Item 9 acknowledges that sample size determination may
not be under the investigator’s control but recommends
that authors make clear whether there was a calculated
sample size or, if not, consider the impact of the sample
size on the reliability of the findings or precision of esti-
mated effects. We anticipate that more details will be
available in later stage studies, but many of the recommen-
dations are also applicable to earlier stage studies. When
specific items of information recommended by REMARK
are not available, these situations should be fully acknowl-
edged in the report so that readers may judge in context
whether these missing elements are critical to study inter-
pretation. Adherence to these reporting recommendations
as much as possible will permit critical evaluation of the
full body of evidence supporting a marker.
Checklist items
Discussion and explanation of the 20 items in the
REMARK checklist (Table 1) are presented. For clarity
we have split the discussion of a few items into multiple
parts. Each explanation is preceded by examples from the
published literature that illustrate types of information
that are appropriate to address the item. Our use of an
example from a study does not imply that all aspects of
the study were well reported or appropriately conducted.
The example suggests only that this particular item, or a
relevant part of it, was well reported in that study. Some
of the quoted examples have been edited by removing
citations or spelling out abbreviations, and some tables
have been simplified.
Each checklist item should be addressed somewhere in a
report even if it can only be addressed by an acknowledg-
ment that the information is unknown. We do not pre-
scribe a precise location or order of presentation as this
one subgroup but not in the other. However, a signifi-
cant effect in one group and a non-significant effect in
the other is not sound evidence that the effect of the
marker differs by subgroup [186,187]. First, a single
test of interaction is required to rigorously assess
whether effects are different in subgroups [188]. Inter-
actions between two variables are usually investigated
by testing the multiplicative term for significance (for
example, in a Cox model). In many studies the sample
size is too small to allow the detection of other than
very large (and arguably implausible) interaction
effects [189]. If the test of interaction is significant,
then further evaluation may be required to determine
the nature of the interaction, particularly whether it is
qualitative (effects in opposite directions) or quantita-
tive (effects in same direction but differing in magni-
tude). Because of the risk of false positive findings,
replication is critical [190].
For continuous variables, categorization is a popular
approach, but it has many disadvantages: the results
depend on the chosen cutpoints (see Item 11 and Box
4), and it reduces the power to detect associations
between marker variables and outcome [191]. The
multivariable fractional polynomial interaction
approach is an alternative that uses full information
from the data and avoids specification of cutpoints. It
allows investigation of interactions between a binary
and a continuous variable, with or without adjustment
for other variables [191,192].
Another approach to assess the effect of treatment
in relation to a continuous variable is the Subpopula-
tion Treatment Effect Pattern Plot [193].
Both approaches were developed in the context of
randomized trials, but they readily apply to observa-
tional prognostic studies investigating the interaction
of a continuous marker with a binary or a categorical
variable such as sex or stage [110,194].
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Page 4 of 39may be dependent upon journal policies and is best left to
the discretion of the authors of the report. We recognize
that authors may address several items in a single section
of text or in a table. In the current paper, we address
reporting of results under a number of separate items to
allow us to explain them clearly and provide examples, not
to prescribe a heading or location. Authors may find it
convenient to report some of the requested items in a sup-
plementary material section, for example on a journal
website, rather than in the body of the manuscript to
allow sufficient space for adequate detail to be provided.
One strategy that has been used successfully is to provide
the information in a supplementary table organized
according to the order of the REMARK items [24]. The
elements of the supplementary table may either provide
the information directly in succinct form or point the
reader to the relevant section of the main paper where the
information can be found. Authors wishing to supply such
a supplementary table with their paper may find it helpful
to use the REMARK reporting template that is supplied as
Additional file 1; it can also be downloaded from http://
www.equator-network.org/resource-centre/library-of-
health-research-reporting/reporting-guidelines/remark.
Introduction
Item 1. State the marker examined, the study objectives,
and any pre-specified hypotheses
Examples
Marker examined
’Using the same cohort of patients, we investigated the
relationship between the type, density, and location of
immune cells within tumors and the clinical outcome of
the patients.’ [25]
Objectives
’The purpose of this study was to determine whether
CpG island hypermethylation in the promoter region of
the APC gene occurs in primary esophageal carcinomas
and premalignant lesions, whether freely circulating
hypermethylated APC DNA is detectable in the plasma
of these patients, and whether the presence and quantity
of hypermethylated APC in the plasma have any rela-
tionship with outcome.’ [26]
’The goal of this study was to develop a sensitive and
specific method for CTC [circulating tumor cell] detec-
tion in HER-2-positive breast cancer, and to validate its
ability to track disease response and progression during
therapy.’ [27]
Hypotheses
“The prespecified hypotheses tested were that TS
expression level and p53 expression status are markers
of overall survival (OS) in potentially curatively resected
CRC.’ [28]
Explanation Clear indication of the particular markers to
be examined, the study objectives and any pre-specified
hypotheses should be provided early in the study report.
Objectives are goals one hopes to accomplish by conduct-
ing the study. Typical objectives for tumor marker prog-
nostic studies include, among others, an evaluation of the
association between tumor marker value and clinical out-
come, or determination of whether a tumor marker con-
tributes additional information about likely clinical
outcome beyond the information provided by standard
clinical or pathologic factors.
The description of the marker should include both the
biological aspects of the marker as well as the time in a
patient’s clinical course when it is to be assessed. The
biological aspects should include the type of molecule or
structure examined (for example, protein, RNA, DNA or
chromosomes) and the features assessed (for example,
expression level, copy number, mutation or transloca-
tion). Most prognostic marker studies are performed on
specimens obtained at the time of initial diagnosis. The
marker could also be assessed on specimens collected at
completion of an initial course of therapy (for example,
detection of minimal residual disease or circulating
tumor cells to predict recurrence or progression) or at
t h et i m eo fr e c u r r e n c eo rp r o g r e s s i o n .At h o r o u g h
description of the marker and timing of specimen collec-
tion is necessary for an understanding of the biological
rationale and potential clinical application.
The stated objectives often lead to the development of
specific hypotheses. Hypotheses should be formulated in
terms of measures that are amenable to statistical evalua-
tion. They represent tentative assumptions that can be
supported or refuted by the results of the study. An
example of a hypothesis is ‘high expression levels of the
protein measured in the tumor at the time of diagnosis
are associated with shorter disease-free survival’.
Pre-specified hypotheses are those that are based on
prior research or an understanding of a biological
mechanism, and they are stated before the study is
initiated. Ideally, a systematic review of the literature
should have been performed. New hypotheses may be
suggested by inspection of data generated in the study.
Analyses performed to address the new hypotheses are
exploratory and should be reported as such. The distinc-
tion between analysis of the pre-specified hypotheses and
exploratory analyses is important because it affects the
interpretation (see Item 19) [9].
Materials and methods
Patients
Item 2. Describe the characteristics (for example, disease
stage or co-morbidities) of the study patients, including
their source and inclusion and exclusion criteria
Examples ‘Inclusion criteria for the 2810 patients from
whom tumour or cytosol samples were stored in our
tumour bank (liquid nitrogen) were: primary diagnosis of
Altman et al. BMC Medicine 2012, 10:51
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potential follow-up); no metastatic disease at diagnosis;
no previous diagnosis of carcinoma, with the exception
of basal cell skin carcinoma and cervical cancer stage I;
no evidence of disease within 1 month of primary surgery
... Patients with inoperable T4 tumours and patients who
received neoadjuvant treatment before primary surgery
were excluded.” [29]
‘We studied 196 adults who were younger than 60 years
and who had untreated primary CN-AML. The diagnosis
of CN-AML was based on standard cytogenetic analysis
that was performed by CALGB-approved institutional
cytogenetic laboratories as part of the cytogenetic compa-
nion study 8461. To be considered cytogenetically normal,
at least 20 metaphase cells from diagnostic bone marrow
(BM) had to be evaluated, and the karyotype had to be
found normal in each patient. All cytogenetic results were
confirmed by central karyotype review. All patients were
enrolled on two similar CALGB treatment protocols (i.e.,
9621 or 19808).’ [30]
’These analyses were conducted within the context of
a completed clinical trial for breast cancer (S8897),
which was led by SWOG within the North American
Breast Cancer Intergroup (INT0102) ... Complete details
of S8897 have been reported elsewhere [citation].’ [31]
Relevant text in the reference cited by Choi et al. [31]:
‘Patients were registered from the Southwest Oncology
Group, Eastern Cooperative Oncology Group, and Can-
cer and Leukemia Group B ... Eligible patients included
premenopausal and postmenopausal women with T1 to
T3a node negative invasive adenocarcinoma of the
breast.’ [32]
Explanation Each prognostic factor study includes data
from patients drawn from a specific population. A descrip-
tion of that population is needed to place the study in a
clinical context. The source of the patients should be spe-
cified, for example from a clinical trial population, a
healthcare system, a clinical practice or all hospitals in a
certain geographic area.
Patient eligibility criteria, usually based on clinical or
pathologic characteristics, should be clearly stated. As a
minimum, eligibility criteria should specify the site and
stage of cancer of the cases to be studied. Stage is particu-
larly important because many tumor markers have prog-
nostic value in early stage disease but not in advanced
stage disease. For example, if a marker is indicative of
metastatic potential, it may have strong prognostic value
in patients with early stage disease but be less informative
for patients who already have advanced or metastatic dis-
ease. For this reason, many studies are restricted to certain
stages. Additional selection criteria may relate to factors
such as patient age, treatment received (see Item 3) or the
histologic type of cancer.
Exclusion criteria might be factors such as prior cancer,
prior systemic treatment for cancer, nonstandard treat-
ment (for example, rarely used, non-approved or ‘off-label’
use of a therapy), failure to obtain informed consent, insuf-
ficient tumor specimen or a high proportion of missing
critical clinical or pathologic data. It is generally not
a p p r o p r i a t et oe x c l u d eac a s ej u s tb e c a u s ei th a saf e w
missing data elements if those data elements are not criti-
cal for assessment of primary inclusion or exclusion cri-
teria (see Item 6a) [33]. In some studies, deaths that have
occurred very early after the initiation of follow-up are
excluded. If this is done, the rationale and timeframe for
exclusion should be specified. To the extent possible,
exclusion criteria should be specified prior to initiation of
the study to avoid potential bias introduced by exclusions
that could be partly motivated by intermediate analysis
results.
When a prognostic study is performed using a subset of
cases from a prior ‘parent’ study (for example, from a
RCT or a large observational study cohort), there may be
a prior publication or other publicly available document
such as a study protocol that lists detailed eligibility and
inclusion and exclusion criteria for the parent study. In
these cases, the prior document can be referenced rather
than repeating all of the details in the prognostic study
paper. However, it is preferable that at least the major
criteria (for example, the site and stage of the cancer) for
the parent study still be mentioned in the prognostic
study paper, and it is essential that any additional criteria
imposed specifically for the prognostic study (such as
availability of adequate specimens) be stated in the prog-
nostic study paper.
Specification of inclusion and exclusion criteria can be
especially challenging when the study is conducted retro-
spectively. The real population that the cases represent is
often unclear if the starting point is all cases with accessi-
ble medical records or all cases with specimens included
in a tumor bank. A review of 96 prognostic studies found
that 40 had the availability of tumor specimens or data as
an inclusion criterion [33]. In some studies, unknown
characteristics may have governed whether cases were
represented in the medical record system or tumor bank,
making it impossible to specify exact inclusion and exclu-
sion criteria. If the specimen set was assembled primarily
on the basis of ready availability (that is, a ‘convenience’
sample), this should be acknowledged.
A flow diagram is very useful for succinctly describing
the characteristics of the study patients. The entrance
point to the flow diagram is the source of patients and
successive steps in the diagram can represent inclusion
and exclusion criteria. Some of the information from this
diagram can also be given in the upper part of the
REMARK profile (see Item 12 for examples).
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important to describe how the specific cases included in
the study were sampled from that population. Item 6a
discusses reporting of case selection methods.
Item 3. Describe treatments received and how chosen (for
example, randomized or rule-based)
Examples ‘Patients were treated with surgery by either
modified radical mastectomy (637 cases) or local tumour
resection (683 cases), with axillary node dissection fol-
lowed by postoperative breast irradiation (695 cases).
Adjuvant therapy with chemotherapy and/or hormone
therapy was decided according to nodal status and hor-
mone receptor results. Treatment protocols varied over
time. From 1975 to 1985, node-negative patients had no
chemotherapy. After 1985, node-negative patients under
50 years of age, with ER and PR negative and SBR
[Scarff-Bloom-Richardson] grade 3 tumours, had
chemotherapy.’ [34]
‘Details of the treatment protocols have been previously
reported. Briefly, patients on CALGB 9621 received induc-
tion chemotherapy with cytarabine, daunorubicin, and
etoposide with (ADEP) or without (ADE) the multidrug
resistance protein modulator PSC-833, also called valspo-
dar. Patients who had CN-AML and who achieved a CR
received high-dose cytarabine (HiDAC) and etoposide for
stem-cell mobilization followed by myeloablative treat-
ment with busulfan and etoposide supported by APBSCT.
Patients unable to receive APBSCT received two addi-
tional cycles of Hi-DAC. Patients enrolled on CALGB
19808 were treated similarly to those on CALGB 9621.
None of the patients received allogeneic stem-cell trans-
plantation in first remission.’ [30]
Explanation A patient’s disease-related clinical outcome
is determined by a combination of the inherent biological
aggressiveness of a patient’s tumor and the response to
any therapies received. The influence of biological char-
acteristics on disease outcome would ideally be assessed
in patients who received no treatment, but usually most
patients will have received some therapy. Many patients
with solid tumors will receive local-regional therapy (for
example, surgery and possibly radiotherapy). For some
types and stages of cancer, patients would almost always
receive systemic therapy (for example, chemotherapy or
endocrine therapy). Sometimes all patients included in a
study will have received a standardized therapy, but more
often there will be a mix of treatments that patients have
received. The varied treatments that patients might
receive in standard care settings can make study of prog-
nostic markers especially challenging.
Because different treatments might alter the disease
course in different ways, it is important to report what
treatments the patients received. The impact of a treat-
ment might also depend on the biological characteristics
o ft h et u m o r .T h i si st h ee s s e n c eo fp r e d i c t i v em a r k e r
research where the goal is to identify the treatment that
leads to the best clinical outcome for each biological class
of tumor (for example, defined by markers) (see Box 1).
The basis for treatment selection, if known, should be
reported. If not known, as will often be the case for ret-
rospective specimen collections, one must be cautious in
interpreting prognostic and predictive analyses. This
concern derives from the possibility that the value of
the marker or patient characteristics associated with the
marker played a role in the choice of therapy, thereby
leading to a potential confounding of effects of treat-
ment and marker. If sufficient numbers of patients are
treated with certain therapies, assessment of the prog-
nostic value of the marker separately by treatment
group (see Box 1) could be considered. However, predic-
tive markers should generally be evaluated in rando-
mized clinical trials to ensure that the choice of
treatment was not influenced by the marker or other
biological characteristics of the tumor.
It is also important to report the timing of therapy rela-
tive to specimen collection since biological characteristics
of a tumor may be altered by the therapies to which it
was exposed prior to specimen collection (see Item 4).
The prognostic value of a marker may be different
depending on whether it was present in the tumor at the
time of initial diagnosis, was present only after the
patient received therapy or whether it is in the presence
of other biological characteristics that emerged as a con-
sequence of therapy.
Specimen characteristics
Item 4. Describe type of biological material used (including
control samples) and preservation and storage methods
Examples
Positive and negative controls
‘Tumor specimens were obtained at the time of surgery
a n ds n a pf r o z e ni nl i q u i dn i t r o g e n ,t h e ns t o r e da t- 8 0 ° C .
Blood samples were collected 24 hours or less before sur-
gery by peripheral venous puncture and were centrifuged
at 1500 × g at 4°C for 10 minutes. The separated plasma
was aliquoted and stored at -80°C for future analysis.
Normal endometrial tissue specimens were obtained
from patients undergoing hysterectomy for benign
gynecologic pathologies. Control plasma specimens were
derived from health check examinees at Yongdong Sever-
ance Hospital who showed no history of cancer or gyne-
cologic disease and had no abnormalities in laboratory
examinations or gynecologic sonography.’ [35]
Preservation and storage methods
‘Fixation of tumor specimens followed standard proto-
cols, using either 10% nonbuffered or 10% buffered for-
malin for 12 hours. Storage time of the archival samples
was up to 15 years. Of the 57 independent MCL cases,
42 tumors had amplifiable cDNA.’ [36]
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24 h, dehydrated in 70% EtOH and paraffin embedded.
Five micrometer sections were cut using a cryostat (Leica
Microsystems, UK) and mounted onto a histological glass
slide. Ffpe [formalin-fixed, paraffin-embedded] tissue
sections were stored at room temperature until further
analysis.’ [37]
Explanation Most tumor marker prognostic studies
have focused on one or more of the following types of
specimens: tumor tissue (formalin fixed and paraffin-
embedded or frozen); tumor cells or tumor DNA iso-
lated from blood, bone marrow, urine or sputum; serum
or plasma. Authors should report what types of speci-
mens were used for the marker assays. As much infor-
mation about the source of the specimen as possible
should be included, for example, whether a tumor sam-
ple was obtained at the time of definitive surgery or
from a biopsy procedure such as core needle biopsy or
fine needle aspirate. For patients with advanced disease,
it should be clearly stated whether tumor samples
assayed came from the primary tumor site (perhaps col-
lected years earlier at the time of an original diagnosis
of early stage disease) or from a current metastatic
lesion and whether the patient had been exposed to any
prior cancer-directed therapies (see Item 3).
Much has been written about the potential confounding
effects of pre-analytical handling of specimens, and several
organizations have recently published articles addressing
best practices for specimen handling [38-40]. Although
the way specimens are collected is often not under the
control of investigators studying prognostic markers, it is
important to report as much as possible about the types of
biological materials used in the study and the way these
materials were collected, processed and stored. The time
of specimen collection will often not coincide with the
time when the marker assay is performed, as it is common
for marker assays to be performed after the specimens
have been stored for some period of time. It is important
to state how long and how the specimens had been stored
prior to performing the marker assay.
The Biospecimen Reporting for Improved Study Qual-
ity (BRISQ) guidelines provide comprehensive recom-
mendations for what information should be reported
regarding specimen characteristics and methods of speci-
men processing and handling when publishing research
involving the use of biospecimens [41]. It is understood
that reporting extensive detail is difficult if not impossi-
ble, especially when retrospective collections are used. In
recognition of these difficulties, the BRISQ guidelines are
presented in three tiers, according to the relative impor-
tance and feasibility of reporting certain types of biospe-
cimen information.
Criteria for acceptability of biospecimens for use in mar-
ker studies should be established prior to initiating the
study. Depending on the type of specimen and particular
assay to be performed, criteria could be based on metrics
such as percentage tumor cellularity, RNA integrity num-
ber, percentage viable cells or hemolysis assessment.
T h e s ec r i t e r i as h o u l db er e p o r t e da l o n gw i t har e c o r do f
the percentage of specimens that met the criteria and
therefore were included in the study. The numbers of spe-
cimens examined at each stage in the study should be
recorded in the suggested flowchart and, particularly, in
the REMARK profile (see Item 12). This information per-
mits the reader to better assess the feasibility of collecting
the required specimens and might indicate potential biases
introduced by the specimen screening criteria.
Often, the specific handling of a particular set of speci-
mens may not be known, but if the standard operating
procedures of the pathology department are known, it is
helpful to report information such as type of fixative used
and approximate length of fixation time; both fixative and
fixation time have been reported to dramatically affect the
expression of some markers evaluated in tissue [42,43].
Information should be provided about whether tissue
sections were cut from a block immediately prior to
assaying for the marker. If tissue sections have been
stored, the storage conditions (for example, temperature
and air exposure) should be noted, if known. Some mar-
kers assessed by immunohistochemistry have shown sig-
nificant loss of antigenicity when measured in cut
sections that had been stored for various periods of time
[44,45]. The use of stabilizers (for example, to protect
the integrity of RNA) should be reported. For frozen
specimens, it is important to report how long they were
stored, at what temperature and whether they had been
thawed and re-frozen. If the specimen studied is serum
or plasma, information should be provided about how
the specimen was collected, including anticoagulants
used, the temperature at which the specimen was main-
tained prior to long-term storage, processing protocols,
preservatives used and conditions of long-term storage.
Typically, some control samples will be assayed as part
of the study. Control samples may provide information
about the marker in non-diseased individuals (biological
controls) or they may provide a means to monitor assay
performance (assay controls).
Biological control samples may be obtained from
healthy volunteers or from other patients visiting a clinic
for medical care unrelated to cancer. Apparently normal
tissue adjacent to the tumor tissue (in the same section)
m a yb eu s e do rn o r m a lt i s s u et aken during the surgical
procedure but preserved in a separate block may also be
used as a control. It is important to discuss the source of
the biological controls and their suitability with respect
to any factors that might differ between the control sub-
jects and cancer patients (for example, other morbidities
and medications, sex, age and fasting status) and have an
Altman et al. BMC Medicine 2012, 10:51
http://www.biomedcentral.com/1741-7015/10/51
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parability of handling of control samples should also be
provided.
Information about assay control or calibrator samples
should also be reported. For example, if dilution series
are used to calibrate daily assay runs or control samples
with known marker values are run with each assay batch,
information about these samples should be provided (see
Item 5).
Assay methods
Item 5. Specify the assay method used and provide (or
reference) a detailed protocol, including specific reagents or
kits used, quality control procedures, reproducibility
assessments, quantitation methods, and scoring and
reporting protocols. Specify whether and how assays were
performed blinded to the study endpoint
Examples ‘Immunohistochemistry was used to detect
the presence of p27, MLH1, and MSH2 proteins in pri-
mary tumor specimens using methods described in pre-
vious reports. Positive controls were provided by
examining staining of normal colonic mucosa from each
case; tumors known to lack p27, MLH1, or MSH2 were
stained concurrently and served as negative controls ...
In this report, we scored the tumors using a modifica-
tion of our previous methods that we believe provides
best reproducibility and yields the same outcome result
as that using our previous scoring method (data not
shown). Nuclear expression of p27 was evaluated in a
total of 10 randomly selected high-power fields per
tumor. A tumor cell was counted as p27 positive when
its nuclear reaction was equal to or stronger than the
reaction in surrounding lymphocytes, which were used
as an internal control. All cases were scored as positive
(>10% of tumor cells with strong nuclear staining),
negative (<10% of tumor cells with strong nuclear stain-
ing), or noninformative.’ [47]
‘Evaluation of immunostaining was independently per-
formed by two observers (KAH and PDG), blinded to
clinical data. The agreement between the two observers
was >90%. Discordant cases were reviewed with a gynae-
cological pathologist and were re-assigned on consensus
of opinion.’ [48]
Explanation Assay methods should be reported in a
complete and transparent fashion with a level of detail
that would enable another laboratory to reproduce the
measurement technique. The term ‘assay’ is used broadly
to mean any measurement process applied to a biological
specimen that yields information about that specimen. For
example, the assay may involve a single biochemical mea-
surement or multiple measurements, or it may involve a
semi-quantitative and possibly subjective scoring based on
pathologic assessment. It has been demonstrated for many
markers that different measurement techniques can
produce systematically different results. For example, dif-
ferent levels of human epidermal growth factor receptor 2
expression have been found using different methods
[49,50]. Variations of p53 expression were observed in
bladder tumors due to different staining techniques and
scoring methods in a reproducibility study comparing
immunohistochemical assessments performed in five dif-
ferent laboratories [51].
Although a complete listing of the relevant information
to report for every class of assay is beyond the scope of
this paper, examples of the general types of technical
details that should be reported are as follows. Specific anti-
bodies, antigen retrieval steps, standards and reference
materials, scoring protocol and score reporting and inter-
pretation (for example, if results are reported as positive
or negative) should be described for immunohistochemical
assays. For DNA- and RNA-based assays, specific primers
and probes should be identified along with any scoring or
quantitation methods used. If another widely accessible
document (such as a published paper) details the exact
assay method used, it is acceptable to reference that other
document without repeating all the technical details. If a
commercially available kit is used for the assay, it is impor-
tant to state whether the kit instructions were followed
exactly; any deviations from the kit’s recommended proce-
dures must be fully acknowledged in the report.
It is important to report the minimum amount of speci-
men that was required to perform the assay (for example,
a5μm section or 5 μg DNA) and whether there were any
other assessments that were performed to judge the suit-
ability of the specimen for use in the study (see Item 4).
Assays requiring a large amount of specimen may not be
feasible for broader clinical application, and study results
may be biased toward larger tumors. If there were any
additional specimen pre-processing steps required (for
example, microdissection or polymerase chain reaction
amplification), these should be stated as well.
It is helpful to report any procedures, such as use of
blinded replicate samples or control reference samples,
that are employed to assess or promote consistency of
assay results over time or between laboratory sites. For
assays in a more advanced state of development, additional
examples could include qualification criteria for new lots
of antibodies or quantitative instrument calibration proce-
dures. If reproducibility assessments have been performed,
it is helpful to report the results of those studies to provide
a sense of the overall variability in the assay and identify
major sources contributing to the variability.
Despite complete standardization of the assay techni-
que and quality monitoring, random variation (mea-
surement error) in assay results may persist due to
assay imprecision, variation between observers or
intratumoral biological heterogeneity. For example, many
immunohistochemical assays require selection of ‘best’
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intensity and percentage of stained cells. The impact of
measurement error is attenuation of the estimated prog-
nostic effect of the marker. Good prognostic performance
of a marker cannot be achieved in the presence of a large
amount of imprecision. It is important to report any stra-
tegies that were employed to reduce the measurement
error, such as taking the average of two or three readings
to produce a measurement with less error, potentially
increasing the power of the study and hence the reliability
of the findings. In multicenter studies, single reviewers or
reference laboratories are often used to reduce variability
in marker measurements, and such efforts should be
noted.
There may be a risk of introducing bias when a
patient’s clinical outcome is known by the individual
making the marker assessment, particularly when the
marker evaluation involves considerable subjective judg-
ment. Therefore, it is important to report whether mar-
ker assessments were made blinded to clinical outcome.
Study design
Item 6. State the method of case selection, including
whether prospective or retrospective and whether
stratification or matching (for example, by stage of disease
or age) was used. Specify the time period from which cases
were taken, the end of the follow-up period and the
median follow-up time
To clarify the discussion we have split this item into two
parts.
a) Case selection
Examples ’We retrospectively analysed tumour samples
from patients who were prospectively enrolled in phase
II and III trials of HDC for HRPBC at the University of
Colorado between 1990 and 2001.’ [52]
’Seven hundred and seventy female patients with pri-
mary invasive breast cancer, diagnosed between 1992
and 1997 at the Institute of Oncology, Ljubljana, were
included in the study. The patients had not been pre-
viously treated, had no proven metastatic disease at the
time of diagnosis and no synchronous or metachronous
occurring cancer. The primary inclusion criterion was
an adequate histogram obtained from an FNA sample
(see below). The diagnosis of carcinoma was therefore
f i r s te s t a b l i s h e db yF N Aa n ds u b s e q u e n t l yc o n f i r m e d
and specified by histological examination in 690 primar-
ily resected tumours (80 patients were not treated surgi-
cally).’ [53]
’Of the 165 patients, all patients who had a pathology
report of a non-well-differentiated (defined as moder-
ately- to poorly-differentiated) SCC were identified. A
matched control group of well-differentiated SCC was
identified within the database. Matching criteria were
(1) age (± 5 y), (2) gender, and (3) site.’ [54]
Explanation The reliability of a study depends impor-
tantly on the study design. An explanation of how
patients were selected for inclusion in the study should
be provided. Reliance on a label of ‘prospective’ or ‘ret-
rospective’ is inadequate because these terms are ill-
defined [55]. It should be clearly stated whether patients
were recruited prospectively as part of a planned marker
study, represent the full set or a subset of patients
recruited prospectively for some other purpose such as
a clinical trial or were identified retrospectively through
a search of an existing database, for example from hos-
pital or registry records or from a tumor bank. Whether
patients were selected with stratification according to
clinicopathologic factors such as stage, based on survival
experience or according to a matched design (for exam-
ple, matched pairs of patients who did and did not
recur) has important implications for the analysis and
interpretation, so details of the procedures used should
be reported.
Authors should describe exactly how and when clini-
cal, pathologic and follow-up data were collected for the
identified patients. It should be stated whether the mar-
ker measurements were extracted retrospectively from
existing records, whether assays were newly performed
using stored specimens or whether assays were per-
formed in real time using prospectively collected
specimens.
In truly prospective studies, complete baseline mea-
surements (marker or clinicopathologic factors) can be
made according to a detailed protocol using standard
operating procedures, and the patients can be followed
for an adequate length of time to allow a comparison of
survival and other outcomes in relation to baseline tumor
marker values. Prospective patient identification and data
collection are preferable because the data will be higher
quality. Prospective studies specifically designed to
address marker questions are rare, although some prog-
nostic studies are embedded within randomized treat-
ment trials. Aside from a potential sample size problem,
ap r o g n o s t i cm a r k e rs t u d ym a yb er e s t r i c t e dt oo n l y
some of the centers from a multicenter RCT. Case selec-
tion within participating centers (for example, inclusion
of only younger patients or those with large tumors) may
introduce bias and details of any such selection should be
reported.
Most prognostic factor studies are retrospective in the
sense that the assay of interest is performed on stored
samples. The benefit of these retrospective studies is that
there is existing information about moderate or long-
term patient follow-up. Their main disadvantage is the
lower quality of the data - clinical information collected
retrospectively is often incomplete and clinicopathologic
data may not have been collected in a standardized fash-
ion (except perhaps if the data were collected as part of a
Altman et al. BMC Medicine 2012, 10:51
http://www.biomedcentral.com/1741-7015/10/51
Page 10 of 39clinical trial). Eligible patients should be considered to be
part of the study cohort and not excluded because of
incomplete data or loss to follow-up, with the amount of
missing data reported for each variable. That allows read-
ers to judge the representativeness of the patients whose
data were available for analysis. (See also Item 10e, Item
12, and Box 2.)
In situations where more complex case selection strate-
gies are used, those approaches must be carefully
described. Given the small size of most prognostic stu-
dies (see Item 9), it is sometimes desirable to perform
stratified sampling to ensure that important subgroups
(for example, different stages of disease or different age
groups) are represented. The stratified sampling may be
in proportion to the prevalences of the subgroups in the
population, or more rare subgroups may be oversampled
(weighted with a higher sampling probability), especially
if subgroup analyses are planned.
Occasionally, patients are sampled in relation to their
survival experience - for example, taking only patients
with either very short or very long survival (excluding
some patients who were censored). Simulation studies
have shown that sampling which excludes certain sub-
groups of patients leads to bias in estimates of prognos-
tic value and thus should be avoided [56]. If a large
number of patients is available for study but few
patients had events, case-control (a case being a patient
with an event, a control being a patient without an
event) sampling methods (matched or unmatched) may
offer improved efficiency.
If standard survival analysis methods are used, unse-
lected cases or random samples of cases from a given
population are necessary to produce unbiased survival
estimates. If more complex stratified, weighted or case-
control sampling strategies are used, then specialized
analysis methods appropriate for those sampling designs
(for example, stratified and weighted analyses or condi-
tional logistic regression) should have been applied and
should be described [57,58] (see Item 10).
b) Time period
Examples ‘... 1143 primary invasive breast tumors col-
lected between 1978 and 1989 ... All patients were exam-
ined routinely every 3-6 months during the first 5 years
of follow-up and once a year thereafter. The median fol-
low-up period of patients alive (n = 584) was 124 months
(range, 13-231 months). Patients with events after 120
months were censored at 120 months because after 10
years of observation, patients frequently are redirected to
their general practitioner for checkups and mammogra-
phy and cease to visit our outpatient breast cancer clinic.’
[59]
‘The estimated median follow-up time, as calculated
by the reverse Kaplan-Meier method, was 4.3 years.’ [60]
Explanation Knowing when a study took place and
over what period participants were recruited places a
study in historical context. Medical and surgical thera-
pies evolve continuously and may affect the routine care
given to patients over time. In most studies where the
outcome is the time to an event, follow-up of all partici-
pants is ended on a specific date. This date should be
given, and it is also useful to report the median duration
of follow-up.
Box 2. Missing data
Missing data occur in almost all studies. The most
common approach to dealing with missing data is to
restrict analyses to individuals with complete data on
all variables required for a particular analysis. These
complete-case analyses can be biased if individuals
with missing data are not typical of the whole sample.
Furthermore, a small number of missing values in
each of several variables can result in a large number
of patients excluded from a multivariable analysis.
The smaller sample size leads to a reduction in statis-
tical power.
Imputation, in which each missing value is replaced
with an estimated value, is a way to include all
patients in the analysis. However, simple forms of
imputation (for example, replacing values by the
stage-specific mean) are likely to produce standard
errors that are too small.
Data are described as missing completely at random
(MCAR) if the probability that a specific observation
is missing does not depend on the value of any obser-
vable variables. Data are missing at random (MAR) if
missingness depends only on other observed variables.
Data are missing not at random (MNAR) if the prob-
ability of being missing depends on unobserved values
including possibly the missing value itself.
Small amounts of missing data can be imputed using
simple methods, but when multiple variables have
missing values, multiple imputation is the most com-
mon approach [130,195,196]. Most imputation meth-
ods assume data are MAR, but this cannot be proved,
and these methods require assuming models for the
relationship between missing values and the other
observed variables. Use of a separate category indicat-
ing missing data has been shown to bias results [195].
The plausibility of assumptions made in missing data
analyses is generally unverifiable. When more than
minimal amounts of data are imputed it is valuable to
present results obtained with imputation alongside
those from complete case analyses, and to discuss
important differences (Item 18).
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be specified. The preferred approach is the reverse
Kaplan-Meier method, which uses data from all patients
in the cohort [61]. Here, the standard Kaplan-Meier
method is used with the event indicator reversed so that
censoring becomes the outcome of interest. Sometimes it
may be helpful to also give the median follow-up of those
patients who did not have the event (in other words,
those with censored survival times). The amount of fol-
low-up may vary for different endpoints, for example
when recurrence is assessed locally but information
about deaths comes from a central register.
It may also be useful to report how many patients were
lost to follow-up for a long period (for example, over one
year) or the completeness of the data compared to that if
no patient was lost to follow-up [62,63].
In a review of 132 reports in oncology journals in 1991
that used survival analysis, nearly 80% included the start-
ing and ending dates for accrual of patients, but only 24%
also reported the date on which follow-up ended [64]. A
review of articles published in 2006 found those dates
reported in 74% and 18% of articles, respectively. Of 331
studies included in 20 published meta-analyses, the time
period during which patients were selected was precisely
defined in 232 (70%) [18].
Item 7. Precisely define all clinical endpoints examined
Examples ‘Survival time was defined to be the period of
time in months from the date of diagnosis to the date of
death from breast cancer. Patients who died from causes
other than those relating to breast cancer were included
for the study, and data for these records were treated as
right-censored cases for evaluation purposes. Relapse
time was defined as the period of time in months from
the date of diagnosis to the date at which relapse was
clinically identified. Data on patients who dropped out
of the study for reasons other than a breast-cancer
relapse were considered right-censored for these ana-
lyses.’ [65]
‘The primary end point was tumour recurrence or
death of a patient. RFS was defined as time from mas-
tectomy to the first occurrence of either locoregional or
distant recurrence, contralateral tumour, secondary
tumour or death; overall survival as time from operation
to death.’ [66]
Explanation Survival analysis is based on the elapsed
time from a relevant time origin, often the date of diag-
nosis, surgery or randomization, to a clinical endpoint.
That time origin should always be specified.
Most prognostic studies in cancer examine few end-
points, mainly death, recurrence of disease or both, but
these end-points are often not clearly defined (see Box 3).
Analyses of time to death may be based on either deaths
from any cause or only cancer related deaths. The end-
point should be defined precisely and not referred to just
Box 3. Clinical outcomes
It is important to clearly define any endpoints examined
(see Item 7). Events typically considered in tumor mar-
ker prognostic studies include death due to any cause,
death from cancer, distant recurrence, local recurrence,
tumor progression, new primary tumor or tumor
response to treatment. The clinical endpoint is reached
when the event occurs. For death, recurrence, progres-
sion and new primary tumor, there is usually interest
not only in whether the event occurs (endpoint
reached), but also the time elapsed (for example, from
the date of surgery or date of randomization in a clinical
trial) until it occurs. Time until last evaluation is used
for patients without an event (time censored). The clini-
cal outcome is the combination of the attainment or
non-attainment of the endpoint and the time elapsed.
Such clinical outcomes are referred to as time-to-event
outcomes. Commonly examined outcomes in tumor
marker prognostic studies are disease-free survival
(DFS), distant DFS, and overall survival (OS). Different
event types are sometimes combined to define a com-
posite endpoint, for example DFS usually includes any
recurrence (local, regional or distant) and death due to
any cause. For composite endpoints, the time-to-event
is the time elapsed until the first of any of the events
comprising the composite endpoint occurs. As recently
shown, a majority of articles failed to provide a com-
plete specification of events included in endpoints [197].
Many clinical endpoints do not have standard defi-
nitions, although there have been some recent efforts
to standardize definitions for some disease sites. The
STandardized definitions for Efficacy End Points
(STEEP) system [67] proposed standardized endpoint
definitions for adjuvant breast cancer trials to address
inconsistencies such as the fact that new primary
tumors, non-cancer death and in situ cancers may or
may not be included as events in DFS for breast can-
cer. Different names may be used interchangeably for
one survival time outcome, for example, recurrence-
free survival and DFS. Furthermore, there is not
always agreement on which endpoint is the most rele-
vant endpoint to consider in a particular disease set-
ting. For example, reliable information about cause of
death is sometimes not available, so considering death
due to any cause is often preferred. In some situations,
for example, in an older patient population with small
risk of dying from the cancer, it can be argued that
death due to cancer is more relevant because it is
expected that many deaths will be unrelated to the
cancer and including them in the endpoint could
make the estimated prognostic effect of the marker
difficult to interpret.
Altman et al. BMC Medicine 2012, 10:51
http://www.biomedcentral.com/1741-7015/10/51
Page 12 of 39as ‘survival’ or ‘overall survival’. If deaths from cancer are
analyzed, it is important to indicate how the cause of
death was classified. If known, it can also be helpful to
indicate what records (such as death certificate or tumor
registry) were examined to determine the cause of death.
If there was a specific rationale for choosing the pri-
mary clinical endpoint, it should be stated. For example,
if the studied marker is believed to be associated with
the ability of a cell to metastasize, an endpoint that
focuses on distant recurrences might be justified. For a
marker believed to be associated with sensitivity to
radiation therapy, local-regional recurrences in a popula-
tion of patients who received radiotherapy following pri-
mary surgery might be relevant.
The lack of standardized definitions also affects the
analysis of recurrence of disease. Relapse-free survival,
disease-free survival (DFS), remission duration and pro-
gression-free survival are the terms most commonly
used; however, they are rarely defined precisely. The first
three imply that only patients who were disease-free after
initial intervention were analyzed (although this is not
always the case), while for progression-free survival all
patients are generally included in the analysis. If authors
analyze disease recurrence they should precisely define
that endpoint, in particular with respect to how deaths
are treated. Similarly, outcomes such as distant DFS
should be defined precisely. Further, standardized defini-
tions across studies would be desirable [67].
Some endpoints require subjective determination (for
example, progression-free survival determined by a
review of radiographic images). For this reason, it can
also be helpful to report, if known, whether the endpoint
assessments were made blinded to the marker measure-
ments. It is helpful to report any additional steps taken to
confirm the endpoint assessments (for example, a central
review of images for progression determination).
The time origin was not stated for at least one endpoint
in 48% of 132 papers in cancer journals reporting survival
analyses [64]. At least one endpoint was not clearly
defined in 62% of papers. Among the 106 papers with
death as an endpoint, only 50 (47%) explicitly described
the endpoint as either any death or only cancer death. In
64 papers that reported time to disease progression, the
treatment of deaths was unclear in 39 (61%). Outcomes
were precisely defined in 254 of 331 studies (77%)
included in 20 published meta-analyses [18]. The authors
noted, however, that ‘this percentage may be spuriously
high because we considered all mortality definitions to be
appropriate regardless of whether any level of detail was
provided’.
Item 8. List all candidate variables initially examined or
considered for inclusion in models
Example ‘Cox survival analyses were performed to
examine prognostic effects of vitamin D univariately
(our primary analysis) and after adjustment for each of
the following in turn: age (in years), tumor stage (T2,
T3, or TX v T1), nodal stage (positive v negative), estro-
gen receptor status (positive or equivocal v negative),
grade (3 v 1 or 2), use of adjuvant chemotherapy (any v
none), use of adjuvant hormone therapy (any v none),
body mass index (BMI; in kilograms per square meter),
insulin (in picomoles per liter), and season of blood
draw (summer v winter). Simultaneous adjustment for
age, tumor stage, nodal stage, estrogen receptor status,
and grade was then performed.’ [68]
Explanation It is important for readers to know which
marker measurements or other clinical or pathological
variables were initially considered for inclusion in models,
including variables not ultimately used. The reasons for
lack of inclusion of variables should be addressed; for
example, variables with large amounts of missing data (see
Box 2). Authors should fully define all variables and, when
relevant, they should explain how they were measured.
All of the variables considered for standard survival ana-
lyses should be measured at or before the study time ori-
gin (for example, the date of diagnosis) [69,70]. (For tumor
markers, this means the measurements are made on speci-
mens collected at or before study time origin even if the
actual marker assays are performed at a later time on
stored specimens.) Variables measured after the time ori-
gin, such as experiencing an adverse event, should more
properly be considered as outcomes, not predictors [71].
Another example is tumor shrinkage when the time origin
is diagnosis or start of treatment. Statistical methods exist
to allow inclusion of variables measured at times after the
start of follow-up (’time-dependent covariates’)[ 7 2 ] ,b u t
they are rarely used and require strong assumptions
[73,74].
A list of the considered candidate variables was pre-
sented in 71% of a collection of 331 prognostic studies
[18]. Of 132 articles published in cancer journals, 18 (13%)
analyzed variables that were not measurable at the study
time origin [64], of which 15 compared the survival of
The endpoints to be examined should be decided on
the basis of clinical relevance. The results for all end-
points that were examined should be reported regardless
of the statistical significance of the findings (see Items
15 to 17 and Box 5). A demonstrated association of a
marker with one of these endpoints does not guarantee
its association with all of the endpoints. For example,
local recurrence may be an indication of insensitivity to
local or regional therapy (such as radiation therapy)
whereas distant recurrence requires that tumor cells
have the ability to metastasize. Different markers may
be indicative of these distinct characteristics.
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who did not respond. Out of 682 observational studies in
clinical journals that used a survival analysis, 127 (19%)
included covariates not measurable at baseline [69].
Item 9. Give rationale for sample size; if the study was
designed to detect a specified effect size, give the target
power and effect size
Examples ‘Cost and practical issues restricted the sample
size in our study to 400 patients. Only 30 centres entered
t e no rm o r ep a t i e n t si nA X I S ,s of o rp r a c t i c a lr e a s o n s ,
retrieval of samples began with these centres within the
U K ,c o n t i n u i n gu n t i lt h et a r g e ts a m p l es i z eo f4 0 0h a d
been reached.’ [75]
‘Assuming a control survival rate of 60% and 50% of
patients with high TS expression or p53 overexpression,
then analysis of tissue samples from 750 patients will
have 80% power to detect an absolute difference of 10%
in OS associated with the expression of either of these
markers.’ [76]
‘Although it was a large trial, FOCUS still lacked
power to be split into test and validation data sets. It
was therefore treated as a single test-set, and positive
findings from this analysis need to be validated in an
independent patient population. A 1% significance level
was used to allow for multiple testing. The number of
assessable patients, variant allele frequencies, and conse-
quent power varied by polymorphism; however, with an
overall primary outcome event rate of 20%, we could
detect differences of 10% (eg, 14% v 24%) between any
two treatment comparisons, and we could detect a lin-
ear trend in genotype subgroups varying by 6% (eg, 13%
v 19% v 25%) with a significance level of 1% and 90%
power ... Even with a dropout rate of 14% for incom-
plete clinical data, there was 85% power at a significance
level of 1% to detect a 10% difference from 14% to 24%
in toxicity for any two treatment comparisons or a lin-
ear trend in genotype subgroups from 13% to 19% to
25%.’ [77]
Explanation Sample size has generally received little
attention in prognostic studies, perhaps because these
studies are often performed using pre-existing specimen
collections or data sets. For several reasons, the basis for
as a m p l es i z ec a l c u l a t i o ni nt h e s es t u d i e si sl e s sc l e a r
than for a randomized trial. For example, the minimum
effect size of interest for a prognostic marker study may
be quite different from that of an intervention study,
and the effect of the marker adjusted for other standard
variables in a multivariable model may be of greater
interest than the unadjusted effect. Authors should
explain the considerations that led to the sample size.
Sometimes a formal statistical calculation will have been
performed, for example calculation of the number of
cases required to obtain an estimated hazard ratio with
prescribed precision or to have adequate power to
detect an effect of a given size. More often sample size
will be determined by practical considerations, such as
the availability of tumor samples or cost. Even in this
situation, it is still helpful to report what effect size will
be detectable with sufficient power given the pre-deter-
mined sample size.
Several authors have addressed the issue of sample size
calculations applicable to prognostic studies [78-80]. The
most important factor influencing power and sample size
requirement for a study with a time-to-event outcome is
the number of observed events (effective sample size),
not the number of patients. For a binary outcome, the
effective sample size is the smaller of the two frequencies,
‘event’ or ‘non-event’. Additional factors, such as the
minimum detectable effect size, distribution of the mar-
ker (or the prevalence of a binary marker), coding of the
marker (whether treated as a continuous variable or
dichotomous; see Item 11 and Box 4) and type of analysis
method or statistical test also have an impact. As a
Box 4. Continuous variables
Many markers are recorded as continuous measure-
ments, but in oncology it is common to convert them
into categorical form by using one or more cutpoints
(Item 11). Common reasons are to simplify the analysis,
to make it easier for clinicians to use marker informa-
tion in decision making, because the functional form of
the influence of a marker is often unknown, and to
facilitate graphical presentation (for example, Kaplan-
Meier curves). Although categorization is required for
issues such as decision making, it has to be stressed
that categorization of continuous data is unnecessary
for statistical analysis. The perceived advantages of a
simpler analysis come at a high cost, as explained
below. The same considerations apply to both the mar-
ker being studied and other continuous variables.
Categorization
Categorization allows researchers to avoid strong
assumptions about the relationship between the mar-
ker and risk. However, this comes at the expense of
throwing away information. The information loss is
greatest when the marker is dichotomized (two
categories).
It is well known that the results of analyses can vary
if different cutpoints are used for splitting. Dichotomiz-
ing does not introduce bias if the split is at the median
or some other pre-specified percentile, as is often done.
If, however, the cutpoint is chosen based on multiple
analyses of the data, in particular taking the value
which produced the smallest P value, then the P value
will be much too small and there is a large risk of a
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studies of patients with a relatively good prognosis, such
as lymph node negative breast cancer, require many
more patients or longer follow-up than studies of
metastatic disease in which events are more frequently
observed. Choice of an endpoint that includes recurrence
as an event in addition to death will also result in more
observed events and higher power, an important reason
as to why DFS is often preferred as an endpoint [81].
Sample size requirements will differ depending on the
goal of the study and stage of development of the mar-
ker. For markers early in the development process,
investigators may be most interested in detecting large
effects unadjusted for other variables and may be willing
to accept higher chances of false positive findings (that
is, a higher type I error) to avoid missing interesting
marker effects. Targeting larger effect sizes and allowing
higher error rates will result in a smaller required sam-
ple size. As a prognostic marker advances in the devel-
opment process, it will typically be studied in the
context of regression models containing other clinically
relevant variables, as discussed in Item 10d. These situa-
tions will require larger sample sizes to account for the
diminished size of marker effects adjusted for other
(potentially correlated) variables and to offer some stabi-
lity even when multiple variables will be examined and
model selection methods will be used.
When the goal is to identify the most relevant vari-
ables in a model, various authors have suggested that at
least 10 to 25 events are required for each of the poten-
tial prognostic variables to be investigated [82-85].
Sometimes the primary focus is estimation of the mar-
ker effect after adjustment for a set of standard vari-
ables, so correctly identifying which of the other
variables are really important contributors to the model
is of less concern. In this situation, sample size need not
be as large as the 10 to 25 events per variable rule
would recommend [86] and other sample size calcula-
tion methods that appropriately account for correlation
of the marker with the other variables are available
[78,87]. Required sample sizes are substantially larger if
interactions are investigated. For example, an interaction
between a marker and a treatment indicator may be
examined to assess whether a marker is predictive for
treatment benefit (see Box 3).
Several studies have noted the generally small sample
size of published studies of prognostic markers. In a
review of lung cancer prognostic marker studies, the
median number of patients per study was 120 [88],
while three quarters of studies in a review of osteosar-
coma prognostic marker literature included fewer than
100 patients [89]. In a systematic review of tumor mar-
kers for neuroblastoma, 122 (38%) of 318 eligible reports
were excluded because the sample size was 25 or lower
[90]. As mentioned above, the number of events is a
more relevant determinant of power of a study, and it is
usually much smaller and often not even reported (see
Item 12).
false positive finding [198]. An analysis based on the
so-called optimal cutpoint will also heavily overesti-
mate the prognostic effect, although bias correction
methods are available [199].
Even with a pre-specified cutpoint, dichotomization
is statistically inefficient and is thus strongly discour-
aged [153,200,201]. Further, prognosis is usually esti-
mated from multivariable models so if cutpoints are
needed as an aid in classifying people into distinct risk
groups this is best done after modeling [153,202].
Categorizing a continuous variable into three or
more groups reduces the loss of information but is
rarely done in clinical studies (by contrast to epide-
miology). Even so, cutpoints result in a model with
step functions which is inadequate to describe a
smooth relationship [110].
Keeping variables continuous
A linear functional relationship is the most popular
approach for keeping the continuous nature of the
covariate. Often that is an acceptable assumption, but
it may be incorrect, leading to a mis-specified final
model in which a relevant variable may not be
included or in which the assumed functional form dif-
fers substantially from the unknown true form.
A check for linearity can be done by investigating
possible improvement of fit by allowing some form of
nonlinearity. For a long time, quadratic or cubic polyno-
mials were used to model non-linear relationships, but
the more general family of fractional polynomial (FP)
functions provide a rich class of simple functions which
often provide an improved fit [203]. Determination of
FP specification and model selection can be done simul-
taneously with a simple and understandable presenta-
tion of results [108,110].
Spline functions are another approach to investigate
the functional relationship of a continuous marker
[101]. They are extremely flexible, but no procedure for
simultaneously selecting variables and functional forms
has found wide acceptance. Furthermore, even for a
univariable spline model, reporting is usually restricted
to the plot of the function because presentation of the
parameter estimates is too complicated.
When the full information from continuous variables
is used in the analysis, the results can be presented in
categories to allow them to be used for tasks such as
decision making.
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nostic studies published between 1987 and 2005 were
assessed to determine the quality of reporting for the
included studies [18]. Only three (0.9%) of the 331 stu-
dies reported that a power calculation had been per-
formed to determine sample size.
Statistical analysis methods
Item 10. Specify all statistical methods, including details of
any variable selection procedures and other model-building
issues, how model assumptions were verified, and how
missing data were handled
After some broad introductory observations about statis-
tical analyses, we consider this key item under eight
subheadings.
All the statistical methods used in the analysis should
be reported. A sound general principle is to ‘describe
statistical methods with enough detail to enable a
knowledgeable reader with access to the original data to
verify the reported results’ [91]. It is additionally valu-
able if the reader can also understand the reasons for
the approaches taken.
Moreover, for prognostic marker studies there are
many possible analysis strategies and choices are made at
each step of the analysis. If many different analyses are
performed, and only those with the best results are
reported; this can lead to very misleading inferences.
Therefore, it is essential also to give a broad, comprehen-
sive view of the range of analyses that have been underta-
ken in the study (see also the REMARK profile in Item
12). Details can be given in supplementary material if
necessary due to publication length limitations.
Analysis of a marker’s prognostic value is usually more
complex than the analysis of a randomized trial, for which
statistical principles and methods are well developed and
primary analysis plans are generally pre-specified. Many of
the marker analysis decisions can sensibly be made only
after some preliminary examination of the data and there-
fore generally only some key features of the analysis plan
can be pre-specified. Many decisions will be required,
including coding of variables, handling of missing data and
specification of models. It would be useful to clarify which
of these decisions were pre-specified and which were
made post hoc or even in deviation from the original
analysis plan.
Reporting of key features of an analysis is important to
allow readers to understand the reasons for the specific
approach chosen and to assess the results. No study seems
yet to have investigated in detail the large variety of statis-
tical methods used and the quality of their reporting, but
the common weaknesses in applying methods and the
general insufficient reporting of statistical aspects of a
multivariable analysis have been well known for many
years. Empirical investigations of published research
articles seem to concentrate more on randomized trials
and epidemiological studies, but the methods and pro-
blems of multivariable models in the latter are similar to
prognostic studies. Concato et al. identified 44 articles
which considered risk factors in the framework of a logis-
tic regression model or a proportional hazard model [92].
All had at least one severe weakness, and they concluded
‘the findings suggest a need for improvement in the
reporting and perhaps conducting of multivariable ana-
lyses in medical research’. Recently Mallett and colleagues
assessed 50 articles reporting tumor marker prognostic
studies for their adherence to some items from the
REMARK checklist [20]. In 49 out of 50 studies (98%), the
Cox model was used. Proportional hazards is one of the
key assumptions of this model but only four articles (8%)
reported testing this assumption (see Item 18). Sigounas et
al. assessed 184 studies on prognostic markers for acute
pancreatitis. Multivariable analyses were performed in
only 15 of them, of which only one provided all details
requested in Item 10 [21]. Although bad reporting does
not mean that bad methods were used, the many studies
identifying specific issues of bad reporting clearly show
that a substantial improvement of reporting of statistical
methods is needed [18,21,33,64,93-98].
In the following sections we consider specific aspects
of analyses under eight headings. Not all aspects will be
relevant for some studies. More extensive discussions of
statistical analysis methods for binary outcome and for
survival data can be found elsewhere [73,99-111].
a. Preliminary data preparation
Example ‘K i 6 7w a sm e a s u r e da sac o n t i n u o u ss c o r e
which is typically positively skewed. Analysis was under-
taken by log transforming Ki67 and using log(Ki67) as a
covariate to investigate whether there is a linear increase
in the probability of relapse with increasing Ki67 value.’
[112]
Explanation Some assessment of the data quality
usually takes place prior to the main statistical analyses
of the data, and some data values may be changed or
removed if they are deemed unreliable. These manipula-
tions and pre-modeling decisions could have a substan-
tial impact on the results and should be reported, but
rarely are [113-117].
There are many examples of steps typically taken in
initial data analyses. The distribution of the marker
values and distributions of any other variables that will
be considered in models should be examined for evi-
dence of extreme values or severe skewness. It may be
appropriate to truncate or omit extreme outliers. Preli-
minary transformations of specific variables (for example,
l o g a r i t h mo rs q u a r er o o t )m a yb ea p p l i e dt or e m o v e
severe skewness. For categorical variables, re-categoriza-
tion is often performed to eliminate sparse categories (for
example, histological types of tumors). Graphical
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the distribution of the marker or other variables (for
example, boxplot; mean, median, SD, range and frequen-
cies) should be described because different methods will
depict features of the data with varying degrees of sensi-
tivity (such as outliers and skewness). If some marker
measurements were judged to be unreliable and conse-
quently omitted or adjusted to lessen their influence in
the analysis, it is recommended these details be reported
as they can be informative about the robustness of the
assay and stability of the analysis results. It is helpful to
report these early steps of the analysis along with the
number of data values that were excluded or somehow
modified (see also Items 12 and 13).
b. Association of marker values with other variables
Example ‘The associations of cathepsin-D with other
variables were tested with non-parametric tests: with
Spearman rank correlation (rs) for continuous variables
(age, ER, PgR), and the Wilcoxon rank-sum test or
Kruskal-Wallis test, including a Wilcoxon-type test for
trend across ordered groups where appropriate, for cate-
gorical variables.’ [29]
Explanation Early steps in an analysis may include an
examination of the relationship of the marker to other
variables being considered in the study. These variables
might include established clinical, pathologic, and demo-
graphic covariates (see Items 13 and 14). If more than
one marker is being evaluated in a study, the relation-
ships between the multiple markers should be examined.
Methods for summarizing associations with other vari-
ables (for example, correlation coefficients, chi-square
tests and t-tests) should be described. Extreme or unu-
sual associations may be relevant to the validity of ana-
lyses and stability of results and may suggest further
data modifications are advisable (see section a above) or
that certain variables are redundant.
c. Methods to evaluate a marker’s univariable asso-
ciation with clinical outcome
Example ‘Median survival time and median DFI [disease
free interval] for the whole test set were estimated using
the Kaplan-Meier product limit method. Univariate
associations between survival time, DFI, and glucose
were examined using Cox proportional hazards regres-
sion models. These analyses examined glucose as a con-
tinuous variable, using an increment of 70 mg/dL to
derive hazard ratios, and adjusted for time of blood
draw to control for circadian effects on glucose levels ...
Wald Chi-square P values were used to calculate uni-
variate statistical significance, and 95% confidence inter-
vals were estimated.’ [118]
Explanation Am a r k e r ’s association with clinical out-
come is of key importance. The first evaluation will
usually be conducted without adjustment for additional
variables, that is, a univariable analysis. The method of
analysis (for example, logrank test or estimated effect
with confidence interval in a Cox regression or a para-
metric model for survival data), including options such
as choice of test statistic (for example, Wald test, likeli-
hood ratio test or score test), should be reported.
Any variable codings or groupings, or transformations
of continuous values applied to the marker variable or
any other variables, should be stated to allow for proper
interpretation of the estimated associations (see Box 4
and Item 11).
In addition, similar analyses may be conducted to
examine the association of other variables with clinical
outcome.
d. Multivariable analyses
Examples ‘A Cox regression model was used with indi-
vidual marker as the exposure variables and OS [overall
survival] (from time of surgery to time of death or end
of current follow-up) as the outcome. The analyses were
adjusted simultaneously for sex, age, tumour size, grade
(World Health Organization), stage and sites as well as
use of post-operative adjuvant therapies.’ [76]
‘Univariable and multivariable Cox regression models
addressed CSM after NU or SU. Covariates consisted of
pathologically determined T stage (pT1 versus pT2 ver-
sus pT3 versus pT4), N stage (N0 versus N1-3), tumour
grade (I versus II versus III versus IV), primary tumour
location (ureter versus renal pelvis), type of surgery (NU
with bladder cuff versus NU without bladder cuff versus
SU), year of surgery, gender (male versus female) and
age. Since pT and pN stages, as well as tumour grade,
m a yc o n t r i b u t et oam u l t i p l i c a t i v ei n c r e a s ei nC S Mr a t e ,
we tested three first-degree interactions between these
variables. Specifically, multivariable interaction tests were
performed between pT and pN stages, between T stage
and tumour grade and between N stage and tumour
grade.’ [119]
‘For both models 1 and 2 a competing risk analysis
was performed using cause-specific hazards. This ana-
lysis follows separate Cox models for each event
assuming proportional hazards. In such competing
risks analyses with two endpoints, it is possible to
interpret both cause-specific hazard ratios simulta-
neously for each risk factor. Cumulative incidence
functions have been displayed for each endpoint. The
proportional hazard assumptions were assessed by
study of the graphs of the Schoenfeld’s residuals; this
technique is especially suitable for time-dependent
covariates.’ [120]
Explanation Univariable analyses are useful but, except
in early studies, are generally insufficient because of the
possible relationship of the marker with other variables.
Thus the prognostic value of the marker after adjust-
ment for established prognostic factors, as estimated
f r o mam u l t i v a r i a b l em o d e l( s e eI t e m1 7 ) ,w i l lb eo f
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justed and adjusted measures of association, it is helpful
to report results from univariable analyses that used the
same general approach as the approach used for the
multivariable analysis. For example, if multivariable ana-
lyses adjusting for standard prognostic factors are based
on a Cox regression model with the log-transformed
marker value as one of the independent variables, then
it is helpful also to report the corresponding results of a
univariable Cox regression analysis. This allows for
direct assessment of how the marker’s regression coeffi-
cient is altered by inclusion of standard covariates in the
model.
Whereas the Cox proportional hazards model allows a
flexible form of baseline hazard, parametric models
assume specific functional forms [109,121,122]. Parametric
models [123] will be statistically more efficient if the
model is correct and may be more easily adaptable to
situations involving complex censoring patterns, but if the
assumed functional form of the baseline hazard is incor-
rect, they can be misleading. It is important that authors
report which model was used.
Multivariable methods can also be used to build prog-
nostic models involving combinations of several candidate
markers or even many hundreds of markers (for example,
gene expression microarray data). Although the same
basic analysis principles apply to these situations, even
greater care must be taken to ensure proper fit of such
models and avoid overfitting, and to rigorously evaluate
the model’s prognostic performance. These topics are cov-
ered in many articles and books [99,101,108,110,124-126]
and are not a focus of this paper.
Investigators may use statistical approaches other than
classic multivariable regression to take into account multi-
ple variables. Such techniques include classification and
regression trees and artificial neural networks. Their
detailed discussion is beyond the scope of the current
guidelines; for details the reader is referred elsewhere
[107].
e. Missing data
Example ‘Thirteen patients (all either ductal carcinoma,
lobular carcinoma or mixed histology) had no grade
information recorded in the data and one patient had
no tumour size recorded. These patients were included
in the analysis using multiple imputation methods to
estimate the missing values. The hazard ratios were
derived from the average effect across 10 augmented
datasets, with the confidence intervals and significance
tests taking into account the uncertainty of the imputa-
tions. The multiple imputation was performed by the
MICE library within the S-Plus 2000 Guide to Statistics
Volumes 1 and 2 (MathSoft, Seattle, WA, USA) ... ‘
[127]
Explanation Almost all prognostic studies have missing
marker or covariate data for some patients because clinical
databases are often incomplete. Also, some marker assays
may not yield interpretable results for all specimens. How-
ever, not all papers report in detail the amount of missing
data and very few attempt to address the problem statisti-
cally [33].
Authors should report the number of missing values for
each variable of interest. They should give reasons for
missing values if possible, and indicate how many indivi-
duals were excluded because of missing data when
describing the flow of participants through the study (see
Item 12). Many authors omit cases without all relevant
information from all analyses or they may vary who is
included according to which variables are included in the
analysis. Including only cases with complete data may
greatly reduce the sample size and potentially lead to
biased results if the likelihood of being missing is related
to the true value (see Box 2) [33,128-131]. Modern statisti-
cal methods exist to allow estimation (imputation) of
missing observations. These issues are clarified in Box 2.
Authors should describe the nature of any such analysis
(for example, multiple imputation) and specify assump-
tions that were made (for example, ‘missing at random’).
In a review of 100 prognostic articles, the percentage of
eligible cases with complete data was obtainable in only
39; in 17 of these articles more than 10% of patients had
some missing data. The methods used to handle incom-
plete covariates were reported in only 32 out of 81 articles
with known missing data [33].
f. Variable selection
Example ‘When using a stepwise variable selection pro-
cedure to identify independent factors prognostic for
survival, variables were added using forward selection
according to a selection entry criterion of 0.05 and
removed using backward elimination according to a
selection stay criterion of 0.05. The importance of a
prognostic factor was assessed via Wald-type test statis-
tics, the hazard ratio and its 95% confidence interval for
survival.’ [132]
Explanation Sometimes several multivariable models
containing different subsets of variables are considered.
The rationale for these choices and details of any model
selection strategies used should be described. The
REMARK profile can provide a concise summary of all
analyses performed (Item 12).
If patients in the study received different treatments,
one or more variables indicating treatments received
can be considered in models, treatment can be used as a
stratification factor or separate models may be built for
each treatment. For many cancer types, there are a few
generally accepted staging variables or other clinical or
pathologic variables that would be available in most
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multivariable models (see also Item 17).
The main multivariable model may sometimes be pre-
specified, which helps to avoid biases caused by data-
dependent model selection. More often, however, many
candidate variables are available and some type of vari-
able selection procedure is sensible in order to derive
simpler models which are easier to interpret and may be
more generally useful [108,133]. It is particularly impor-
tant to state if the variables included in a reported
model were determined using variable selection proce-
dures. Any selection procedures used should be
described (for example, stepwise regression or backward
elimination) along with specif i cc r i t e r i au s e dt od e t e r -
mine inclusion or exclusion of variables from the model
(for example, P values) or to select a best fitting model
(for example, Akaike information criterion) [101]. It is
well known that, unless sample sizes are large, use of
variable selection procedures will lead to biased para-
meter estimates and exaggerated measures of statistical
significance [66,121,134]. For this reason, Item 17
requests that results from a particular multivariable
model which includes the marker along with ‘standard’
prognostic variables, regardless of statistical significance,
be reported.
g. Checking model assumptions
Examples ‘In the basic form of the Cox regression
model, the coefficients corresponded to the logarithm of
the HR and were constant in time. This assumption was
graphically evaluated by means of smoothed Schoenfeld
residuals and tested as suggested by Grambsch and
Therneau.’ [135]
‘The proportional hazards assumptions were checked
by plots of log(- log survival time) versus log time.’ [136]
‘We evaluated the proportional hazards assumption by
adding interaction terms between the time-dependent
logarithm of follow-up time plus 1 and tamoxifen treat-
ment, ERaS118-P status, or both and found no evidence
for nonproportional hazards (P = .816, .490, and .403,
respectively).’ [24]
Explanation Any statistical model, univariable or multi-
variable, makes certain assumptions about the distribu-
tions of variables or the functional relationships between
variables. For example, the Cox proportional hazards
regression model commonly used for survival data
requires several important assumptions, including pro-
portional hazards and linear relationships between con-
tinuous covariates and the log hazard function.
Proportional hazards assumptions are often violated
when there is long follow-up, for example, for certain
types of cancers in which a portion of patients can be
considered cured. How the variables are coded or trans-
formed will also affect the appropriateness of linear ver-
sus non-linear relationships (see Item 11 and Box 4).
Methods used to empirically check model assumptions
should be reported. For example, residual plots and mod-
els containing time-by-covariate interactions are often
used to diagnose departures from linearity and propor-
tional hazards [122,137-139]. Influential points and out-
liers can often be detected by diagnostic plots such as
added variable plots [140]. Parametric survival models,
such as lognormal or Weibull models, make additional
assumptions about the distribution of the survival times
[123]. The suitability of parametric models can be
checked using methods such as residual plots and good-
ness of fit tests [109,121]. Many extensions of the Cox
model have been proposed to handle departures from the
basic assumptions [138,139] but they will not be dis-
cussed here. More complex models require larger sample
sizes than often are available in tumor marker prognostic
studies to avoid overfitting to noise in the data [107,141].
Alternative models evaluated for purposes of sensitiv-
ity analyses should also be described (see Item 18).
h. Model validation
Examples ‘For internal validation of the multivariate
models, 1000 bootstrap samples were created and step-
wise Cox regression analysis was applied to each sample.
The relative frequencies of inclusions of the respective
factors were calculated.’ [142]
‘For this study, and future studies using this TMA, the
primary investigator is given access to all clinical, out-
come, and TMA data from the training set only. The
training set is used to generate and refine hypotheses
regarding the biomarker under study. Significant find-
i n g sa r et h e nf o r m a l l yp r e s e n t e d. . .T h o s ef i n d i n g sc o n -
sidered to be of clinical and scientific interest are then
re-tested on the validation set. A separate researcher
who did not participate in the training set analysis per-
forms the re-testing on the validation set. Our statistical
approach is intended to minimize false positive results,
particularly with subgroup analysis.’ [143]
Explanation Invariably, the strongest evidence for the
validity of results is confirmation of the findings on data
not involved in the original analysis [144,145]. The ideal
approach is to confirm findings from the main (final)
model on completely independent data, preferably col-
lected by different investigators but under pre-defined
appropriate conditions. If successful, this approach would
indicate that the results are transportable to other settings.
This would be a type of ‘external validation’. A prospec-
tively designed and conducted clinical trial is the strongest
form of validation, but trials designed with the primary
objective to validate a prognostic marker or model are
rare. More often, evaluations of markers occurring within
trials are secondary aims in trials primarily designed to
evaluate a treatment or other intervention. The marker
evaluation could occur during the trial, or the evaluation
might take place even years after completion of the trial
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This latter option has been referred to as a ‘prospective-
retrospective’ design, and it can provide a high level of evi-
dence for the utility of a marker if conducted under appro-
priate conditions [146]. Complete specification of the
marker assay method and model (if relevant), a pre-speci-
fied analysis plan, and enforcement and documentation of
lock-down of marker analytical results prior to unblinding
of clinical outcome data (see also Item 5) are among the
conditions that should be satisfied for a rigorous prospec-
tive-retrospective validation.
A completely independent data set (a ‘similar’ study)
often will not be available, but ‘internal’ validation pro-
cedures, such as cross-validation, bootstrapping or other
data resampling methods [133,147], are useful to give
insights into critical issues such as bias of regression
parameter estimates, overoptimism of prognostic model
discriminatory ability or stability of the model derived
(see also Item 18). Internal validation involves holding
out some portion of the data (’test set’) while a model is
built on the remaining portion (’training set’); when the
model is completely specified on the training set, it is
then evaluated (tested) on the held-out data. A limita-
tion of internal validation is that there may be biases
affecting the entire data set that will not be detected by
internal validation because the biases will affect the
training and test sets equally [46]; however, if a model
has been seriously overfitted to random noise in the
training set, properly performed internal validation
should reveal failure of the model on the test data. The
study report should include a description of any valida-
tions that were performed, internal or external.
For internal validation, the specific validation algo-
rithm used should be described (for example, boot-
strapping, 10-fold or leave-one-out cross-validation)
[147-149]. If a study performs any external validation,
basic details of the study population, design and ana-
lysis approach should be provided. It should be clari-
fied whether the external validation sample came
from the same or different centers or periods as the
samples used to develop the model. In cases where
t h ew h o l es t u d yr e p r e s e n t savalidation of a previously
developed model this should be stated, along with
proper reference to the previous study that developed
that model.
Item 11. Clarify how marker values were handled in the
analyses; if relevant, describe methods used for cutpoint
determination
Examples ‘In the regression models, steroid receptors
content and age were considered as continuous vari-
ables, the latter in its original measure scale and the for-
mer in terms of its natural logarithms because of the
positive skew of its distribution. Null values for steroid
receptor content were arbitrarily set to 1 considering a
sensitivity threshold value of 2 fmol/mg of cytosolic
protein.’ [135]
‘Hazard ratios (HRs) and 95% CIs for CRP and SAA
tertiles were estimated using Cox proportional hazards
regression ... CRP and SAA values were log transformed
to account for skewness, and HRs and 95% CIs were
generated for these continuous measures.’ [150]
‘As there was no clinically defined cutoff point for serum
IL-6 level, the median was used to divide the patients into
two groups (low versus high serum IL-6 level).’ [151]
‘In the absence of a reliable gold standard and following
distributional studies, we used the 25th percentile of
observed hormonal receptor mRNA expression levels and
the median of observed MAP-Tau mRNA levels as thresh-
olds for categorization of tumors to positive or negative
cases.’ [152]
Explanation Many markers are measured as continuous
variables. A central question is how to analyze these vari-
ables, including how to incorporate them in a multivari-
able model. The same considerations apply to several
standard variables, such as age and tumor size.
Two main approaches are to keep the variables as con-
tinuous (but not necessarily assume a linear relation with
the outcome), or to group the data into categories.
Although categorization is ubiquitous in cancer studies,
there are some major concerns about that approach, as
discussed in Box 4 [153]. The common practice of using
only two categories makes it impossible to detect any non-
linearity in the relation between the variable and outcome.
However, for later clinical use, dichotomization may be
necessary.
Authors should report how each continuous variable
was incorporated into the analyses. For categorized vari-
ables, they should specify the cutpoints and how they were
chosen. It is especially important to declare any cutpoints
chosen after examining many options (see Box 4). For
continuous variables, authors should clarify whether the
data were kept on the original scale or, say, log trans-
formed, and indicate whether the relationship was mod-
eled as linear or non-linear, and how. If treated as linear, it
is helpful to report whether the assumption of a linear
relationship for continuous variables was checked (Box 4).
Similar concerns relate to variables with three or more
ordered categories, such as Karnofsky score. For markers
and other variables with several categories (for example,
f r o mt h r e et os i x )i ti si m p o r t a n tt os p e c i f yh o wt h e y
were treated in the analyses. If dummy variables were
created, it is important to specify how they were defined
and analyzed [110]. If multiple methods of coding
dummy variables are considered in the analysis, there is a
risk of selective reporting of the results that look most
interesting.
Reviews of published prognostic factor studies show that
categorization is very common, with almost all studies
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Further, there is usually considerable variation in cut-off
values across studies, hindering a sound comparison of
results. For example, a review of p53 in bladder cancer
found that definitions of positive p53 staining cut-off
values ranged from 1% to 75% [154].
Results
Data
Item 12. Describe the flow of patients through the study,
including the number of patients included in each stage of
the analysis (a diagram may be helpful) and reasons for
dropout. Specifically, both overall and for each subgroup
extensively examined report the number of patients and the
number of events
Examples ‘Tumor samples from 375 patients were sent
to the central laboratory for EGFR assays by IHC, and
evaluable assay results were obtained for 325 patients
(87%). Among the 50 patients with unevaluable results,
38 (76%) had insufficient tumor cells in their tumor
sample, six (12%) had extensive necrosis, three (6%) had
inadequate control staining, two (4%) had poor tumor
preservation, and one (2%) had a broken slide.’ [155]
See also Figure 1.
Explanation The interpretation of prognostic studies
depends on having a good understanding of the patients
included in the study, the methods used, the analyses
conducted and the amount of data available at each
stage. In contrast to RCTs, exploratory analyses play a
much more important role (see Item 10). In general,
several analyses are conducted of which only some are
fully reported, with the results of others mentioned only
briefly in the text (and easily overlooked) or not
reported at all. This selective reporting practice gives
rise to biased results and biased interpretation and
should be avoided. Important information, such as the
effective sample size (see Item 9), is usually not given
for many analyses. At present, hardly any report fully
meets the needs of readers [20,21].
One way to ensure completeness of reporting of key
information is via a structured display. Even for RCTs,
which are relatively straightforward, it is often impossible
to understand from the text why the numbers of patients
in analyses differs from the numbers enrolled in the trial.
Thus the CONSORT flow diagram [8] has become a
widely used simple depiction of the flow of participants
in an RCT from enrolment through to inclusion in the
final analysis.
Analyzing and reporting prognostic studies is in gen-
eral more complicated than for RCTs. Therefore, we
suggest two complementary displays that authors can
use to summarize key aspects of a prognostic study,
Figure 1 Example of a participant flow diagram. [177]
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analyses performed. A flow diagram provides an easy to
follow view of the major changes in the population as
the study proceeds; a study profile (see below) provides
a succinct summary of the analyses performed and the
data used in them.
The upper part of a study profile can be used to show
the derivation of the sample of patients included in the
study. It is analogous to the CONSORT [8] and
STROBE [156] flow diagrams, but gives the information
i nam o r ec o n d e n s e dw a ya n dm a ym a k eaf l o wd i a -
gram, as shown in the examples, redundant (see also
Item 2). Its inclusion in reports of prognostic studies
would help to clarify the extent to which the analyzed
patients were selected from a larger series.
Knowing how many patients were included in a
study is important, but information should be given
about the amount of data available for each analysis.
Missing values (see Box 2) are much more common in
retrospective studies than in prospective studies due to
the use of historical data. The complete case analysis is
t h em o s tw i d e l yu s e dm e t h o d( s e eI t e m1 0 e ) ;a sac o n -
sequence, the number of patients and events will often
vary across analyses according to the choice of adjust-
ing variables. Further, the outcome measure and any
restriction to a subgroup also affect the number of
patients and events. These numbers are a key element
determining the statistical reliability of any analysis.
Readers thus need to understand which patients (and
how many events) were included in each analysis, and
also which variables were used. For all of these rea-
sons, a standard format for reporting all analyses per-
formed would be extremely helpful and is strongly
recommended.
We developed a two-part study profile which has
already been used in a paper on the reporting of prog-
nostic studies [20]. As illustrated in the examples below,
the first part gives details about how the marker of
interest was handled in the analysis and which further
variables were available. In addition, key information
c a nu s e f u l l yb ep r o v i d e di nt h i sp a r ta b o u tt h ep a t i e n t
population, inclusion and exclusion criteria, and the
number of eligible patients and events for each outcome
in the full data set. In the first example (Table 2), the
number and reasons for patients excluded are given, but
not the numbers for each reason. These numbers can
easily be given and would help readers to assess a study.
As the patient population is often heterogeneous with
regard to stage of the disease, treatment and other factors,
it is common practice to assess the marker in several more
homogeneous subgroups of the population. Furthermore,
several outcomes (for example, DFS, distant DFS or overall
survival, OS) are usually considered. Figures showing
Kaplan-Meier estimates are often presented for a
univariable assessment, for a continuous marker divided
into subgroups. However, the results of further analyses
and details about variables in a multivariable model are
often only briefly summarized in the text or perhaps not
mentioned at all. (See Box 5 for discussion of the implica-
tions of selective reporting.)
To help the reader understand the multiplicity of ana-
lyses and better assess the results, the second part of the
proposed profile gives an overview of all analyses. Nearly
all reports of prognostic marker studies include univari-
able, multivariable and subgroup analyses. Several multi-
variable analyses are often reported in prognostic marker
studies. It is critical to know which variables were available
in order to determine the most appropriate multivariable
analysis for a given study. Also, it is frequently unclear
which variables have been adjusted for in each analysis.
Often, some analyses and their results are mentioned in
just one sentence in the text (for example, ‘the effect of
marker x was the same in subgroup A’ or ‘the effect of
marker x was unchanged when adjusting for the three
variables v1, v2 and v3’) and will only be noticed by a care-
ful reader. Further, it may not be obvious that some ana-
lyses were based on only a small number of patients and a
handful of events.
Reporting of estimated effects from models and esti-
mates of survival curves often concentrate on DFS and
results from OS are less prominently shown. One reason
may be the larger number of DFS events, even though OS
may be the more important outcome. Reporting the num-
ber of deaths may reveal that the effective sample size is
very small. To assess the value of any analysis it is impor-
tant to know both the number of patients and events (the
effective sample size) for the outcome.
We attempt to illustrate the issues described above in
relation to two rather different studies. The study by
Pfisterer et al. [157] investigated the effect of ploidy in
advanced ovarian cancer (see Table 2). As the disease
has a very bad prognosis, the authors decided to con-
sider OS as the only outcome of interest. Part (a) pre-
sents the information about the patients, treatments and
variables studied. Part (b) gives an overview of all ana-
lyses with numbers of patients and events, and the
reader is guided to where those results are presented in
the report.
The study by Wadehra et al. [158] investigated the
expression of epithelial membrane protein-2 in patients
with endometrial adenocarcinoma (Table 3). In contrast
to the first example, both DFS and OS were investi-
gated. Several features are immediately apparent: the
sample sizes for these two outcomes differ, only one
multivariable analysis was reported for each of the two
outcomes, and the marker of interest did not enter the
final model for OS. The profile thus gives reviewers, edi-
tors and readers a greater opportunity to evaluate what
Altman et al. BMC Medicine 2012, 10:51
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Indeed, creating such a profile should be helpful to
authors too.
Because of the large variety of analyses that may be per-
formed, the profile for a specific study may need to differ
in structure from these examples. However, we propose
that the key elements of the profile, as shown in the two
examples, be included. Wide adoption of this presentation
format would considerably aid the transparent reporting
of prognostic marker research and help to remedy the
widespread deficiencies that have been well documented.
The need for a study profile is supported by the diffi-
culty we encountered in finding published articles that
presented all the information to construct a profile. Also, a
review of 50 articles in cancer journals in 2006 to 2007
reporting tumor marker prognostic studies found that
typically only half of the REMARK profile items were
reported and these were often difficult to find [20]. Half of
the articles did not report the number of events for any
analyses or outcomes.
Item 13. Report distributions of basic demographic
characteristics (at least age and sex), standard (disease-
specific) prognostic variables, and tumor marker, including
numbers of missing values
Examples See Table 4, Figure 2 and Figure 1 in [29]
Explanation Inclusion and exclusion criteria (Item 2)
describe the target patient population. The group of
patients included in a particular study is a sample from
that population. Distributions of basic demographic vari-
ables and standard prognostic variables should be
reported to characterize the group of patients who were
actually studied. These demographic and standard prog-
nostic variables are often the variables to be considered
for inclusion in multivariable analyses (see Item 8). Dis-
tributions of age and sex should routinely be reported. If
available, racial or ethnic distributions are sometimes
helpful to report, as some markers have shown associa-
tion with race and/or ethnicity (for example, the positive
association between epidermal growth factor receptor
gene mutation and Asian ethnicity). For most types of
Table 2 Example of the REMARK profile illustrated using data from a study of ploidy in patients with advanced
ovarian cancer [157] (from [20]).
a) Patients, treatment and variables
Study and marker Remarks
Marker (If non-binary: how was marker analyzed? continuous or categorical.
If categorical, how were cutpoints determined?)
M = ploidy (diploid, aneuploid)
Further variables
(variables collected, variables available for analysis, baseline variables, patient
and tumor variables)
v1 = age, v2 = histologic type, v3 = grade, v4 = residual tumor, v5 =
stage, v6 = ascites
a, v7 = estrogen
a, v8 = progesterone
a, v9 = CA-125
a
Patients n Remarks
Assessed for eligibility 257 Disease: Advanced ovarian cancer, stage III and IV
Patient source: Surgery 1982 to 1990, University Hospital
Freiburg
Sample source: Archived specimens available
Excluded 73 General exclusion criteria
b, non-standard therapy
b,
coefficient of variation > 7%
b
Included 184 Previously untreated.
Treatment: all had platinum based chemotherapy after
surgery
With outcome events 139 Overall survival: death from any cause
b) Statistical analyses of survival outcomes
Analysis Patients Events Variables
considered
Results/remarks
A1: Univariable 184 139 M, v1 to v5 Table 2, Figure 1
A2: Multivariable 174 133 M, v1, v3 to
v5
Table 3 [v2 omitted because many
missing data; Backward selection,
see text]
A3: Effect for ploidy adjusted for v4 184 139 M, v4 Figure 2 [Based on result of A2]
A4: Interaction: ploidy and stage 175 133 M, v1, v2, v4,
v5
See text
A5: Ploidy in stage subgroups
v5 = III 128 88 M Figure 3
v5 = IV 56 51 M Figure 4
aNot considered for survival outcome as these factors are not considered as ‘standard’ factors and/or number of missing values was relatively large;
bvalues not
given in the paper.
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prognostic variables (for example, pathologic stage infor-
mation including nodal status, tumor size and presence
of metastases, or clinical measures such as performance
status), and distributions of these variables should be
reported. The number of patients with missing values
should be reported for each variable as should the num-
ber of patients for whom there are complete data on all
variables or on those variables whose effect on a survival
outcome is assessed in a multivariable model.
If patients are a subsample from a randomized trial or
large defined cohort it is helpful to compare the charac-
teristics of those with and without tumor marker mea-
surements to help judge the generalizability of the
findings.
A thorough description of the distribution of the mar-
ker of interest should also be provided. The distribution
may be described by a frequency table or bar chart for
categorical variables or numerically by use of summary
statistics such as mean, median, percentiles, range and
standard deviation for continuous variables. Figures
such as histograms or boxplots are informative for con-
tinuous variables. Presenting continuous data only in
categories is insufficient (see Box 4), but grouped data
can be presented in addition to the summary statistics.
Analysis and presentation
Item 14. Show the relation of the marker to standard
prognostic variables
Examples See Tables 5, 6 and 7.
‘On analyzing the relationship between receptor data
and the above-mentioned prognostic factors, we found a
significant correlation between patient age and ER (ICC
[immunocytochemistry], r = .46; DCC [dextran-coated
charcoal], r = .43). While tumors from patients ≤50 years
old were ER positive in only 41% (ICC) and 67% (DCC) of
Box 5. Selective reporting
Publication of the findings of only some of the research
that was done in a field will lead to bias when publica-
tion choices are made with the knowledge of study
findings. Selection is mostly in relation to whether or
not results were statistically significant (P < 0.05) or
show a trend in the favored direction. Selective report-
ing of studies, or selective reporting of only some ana-
lyses within studies, both lead to larger effects being
seen in smaller studies, and literature that is biased
towards overestimating the prognostic importance of
tumor markers [204].
Evidence of biased non-publication of whole studies
has been accumulating for many years, but recently
research has demonstrated evidence of additional
within-study selective reporting [205,206]. Empirical
evidence of study publication bias and within-study
selective reporting primarily relates to randomized con-
trolled trials, but it is likely to be a major concern for
prognostic studies. Publication bias in prognostic stu-
dies may be worse as many of these studies are based
on retrospective analysis of existing clinical databases.
Indeed, there is no indication that a particular marker
or marker-related hypothesis has been studied until
and unless it is published. A review of 1915 articles on
cancer prognostic markers found that less than 1.5%
were fully negative, in that they did not present any sta-
tistically significant prognostic results [207]. A systema-
tic review of studies of Bcl2 in non-small cell lung
cancer revealed that almost all the smaller studies
showed a statistically significant relationship between
Bcl2 and risk of dying with large hazard ratios, whereas
the three large studies were all non-significant and
showed much smaller effects [208]. A review of the
prognostic importance of TP53 status in head and neck
cancer showed clearly that published studies had larger
effects than unpublished studies [17,209]. Such studies
point to the value of a register of biomarker studies
[210].
Possible within-study selective reporting could take
several forms. For example, in cancer studies two
principal outcomes are time to death (overall survival)
and time to recurrence of disease (that is, disease-free
survival). Many studies report only one of these out-
comes. Although both unadjusted and adjusted results
are usually provided, some studies only report unad-
justed results [211]; in general they will be larger than
adjusted results. Similar concerns relate to selective
reporting of only some subgroup analyses performed.
Reports should include discussion of all analyses per-
formed and whether they were pre-planned (see Item
12). Often a number of exploratory analyses are
conducted. The exploratory nature should be clearly
s t a t e d .R e a s o n sf o rt h e s ea n a l y s e sa n dr e s u l t sc a nb e
summarized in a few sentences. A further issue is that
some results are only reported partially, for example,
solely as ‘not significant’, preventing that study from
contributing to a subsequent meta-analysis.
Problems that can arise from selective reporting are
discussed in relation to clinical endpoints, the flow of
patients through the study and reporting of events and
estimated effects for all variables in Items 7, 12 and 16,
respectively. Obviously, selective reporting is an impor-
tant impediment to reliable assessment of a marker
according to evidence based medicine criteria
[19,212-214].
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77% (ICC) and 81% (DCC) of cases. In addition, a weakly
significant negative correlation was found between the
number of positive axillary nodes and ER (ICC, r = -18;
DCC. r = -.15) and a weakly significant negative correla-
tion between tumor grade and ER (ICC, r = -.17) as well
as PR (ICC, r = -.24; DCC, r = -.14). No significant correla-
tion between steroid receptors and the remaining prog-
nostic factors, tumor size and histology, was found.’ [159]
Explanation The association of the tumor marker with
standard prognostic variables should be described. A new
marker is most useful if it provides clinically important
information beyond that given by existing prognostic
variables or indices, or it offers an advantage over other
markers because it is easier to measure or quantify. Often
a new marker has at least a modest association with some
other standard prognostic markers. In a multivariable
model, modest correlations between the marker value
and other standard variables in the model will influence
the estimated effect of the marker and increase its stan-
dard error. If there are very strong correlations between
two or more variables in a model (for example, between
age, estrogen and progesterone receptor in breast can-
cer), effects estimated from the model can be very
unstable and difficult to interpret, requiring great care in
model building (see Item 10d). Further, if the marker has a
very high correlation with routinely available standard
prognostic variables that can be measured more easily,
reproducibly and inexpensively, it is unlikely to have
clinical value either as a replacement for the standard vari-
ables or as an adjunct to the standard variables. Therefore,
it is important to report the strength and nature of the
association between the marker and other variables. Addi-
tionally, it is helpful to summarize the associations
between the other standard variables, especially when mul-
tivariable models containing combinations of standard
variables are being considered.
Graphical displays can be particularly helpful in convey-
ing the nature of associations between the marker and
other variables. For two continuous variables (for example,
a continuous marker versus a continuous standard variable
or prognostic index), scatterplots are most informative, and
these may be accompanied by summary measures such as
correlations. The study report should include a summary
description of the findings of these association assessments.
Often the tumor marker and other standard variables are a
mix of continuous and categorical measurements. Displays
such as boxplots, dotplots or histograms of the continuous
measures for each of the levels or combinations of the cate-
gorical variables can be informative. Categorizing continu-
ous variables should be avoided (see Box 4). If all variables
are categorical, tables showing cross-classifications of cases
by categories of the marker and categories of each of the
standard variables are useful. Such descriptive analyses are
also helpful for interpretation of multivariable models and
assessment of the stability of those models.
I no r d e rf o ram a r k e rt op r o v i d es o m ei n f o r m a t i o n
independent of the values of existing variables, it must
Table 3 Example of the REMARK profile illustrated using data from a study of expression of epithelial membrane
protein-2 in patients with endometrial adenocarcinoma [158].
a) Patients, treatment and variables
136 Patients with endometrial adenocarcinoma assessed for eligibility, 37 excluded (33 no informative immune histochemistry, 4 without
clinical information)
99 Patients included, stages IA to IVB
Formalin fixed, paraffin embedded endometrial tissue samples, Department of Pathology, UCLA Los Angeles, USA
Marker (and how was the marker
handled in analysis?)
M = epithelial membrane protein-2
Immunoreactive score obtained by multiplying subscores for intensity (0 to 3+) and distribution of
immunoreactivity (0 to 4+) grouped as negative (score 0), weak (1 to 3) or moderate-to-strong (4 to 12)
Outcomes: DFS (97 patients, 42 events), OS (99 patients, 32 events)
Further variables: v1 = age, v2 = ER, v3 = PR, v4 = vascular invasion, v5 = stage, v6 = histology, v7 = grade
b) Statistical analyses of survival outcomes
DFS OS
Aim Patients Events Patients Events Variables
considered
Results/remarks
A1: Univariable 97 42 99 32 M, v1-v7 Figure 3, Figure 4, Table 2, Table 3
DFS: except v1 all significant
OS: all significant
A2: Multivariable 97 42 99 32 DFS: M, v2-v7 Table 4, Table 5
OS: M, v1-v7 In multivariable analysis: all significant in A1, then
stepwise selection
Variables in final models: DFS: M, v5, v6; OS: v4, v6,
v7 (M is not included)
DFS: disease-free survival; ER: estrogen receptor; M: epithelial protein; PR: progesterone receptor; OS: overall survival.
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That variation can take different forms. The marker
might show variation within all possible ranges of the
existing variables, or it might show variation within some
ranges of existing variables but not within others. This
information, together with an assessment of how the var-
iation in the marker correlates with clinical outcome (see
Items 15-17), will suggest those patients for whom the
new marker might provide clinically useful new
information.
Table 4 Example of tabular reporting of patient characteristics [180].
Patients
All CK-19 mRNA + CK-19 mRNA -
Characteristic Number % Number % Number % P
Patients enrolled 444 100 181 40.8 263 59.2
Age, years
Median 54 54 55
Range 26 to 78 26 to 74 30 to 78 0.752
Menopausal status 0.075
Premenopausal 191 43 87 45.5 104 54.5
Postmenopausal 253 57 94 37.2 159 62.8
Tumor size 0.648
T1 157 35.4 61 38.9 96 61.1
T2 251 56.5 103 41 148 59
T3 36 8.1 17 47.2 19 52.8
Histology grade 0.316
I/II 204 46 87 42.6 117 57.4
III 191 43 72 37.7 119 62.3
Unknown 49 11 22 27
Infiltrated axillary lymph nodes 0.538
0 163 36.7 61 37.4 102 62.6
1 to 3 122 27.5 53 43.5 69 56.5
≥4 159 35.8 67 42.1 92 57.9
ER 0.779
Negative 175 39.4 71 40.6 104 59.4
Positive 260 58.6 109 41.9 151 58.1
Unknown 9 2 1 8
PR 0.126
Negative 234 52.7 89 38 145 62
Positive 201 45.3 91 45.3 110 54.7
Unknown 9 2 1 8
HER2 0.897
0, 1+ 290 65.3 122 42.1 168 57.9
2+ 53 11.9 21 39.6 32 60.4
3+ by IHC 88 19.8 35 39.8 53 60.2
Unknown 13 3 3 10
Adjuvant chemotherapy 0.425
CMF 43 9.7 14 32.6 29 67.4
FEC 209 47.1 84 40.2 125 59.8
EC-T 192 43.2 83 43.2 109 56.8
Surgery 0.478
L 310 69.8 123 39.7 187 60.3
M 134 30.2 58 43.3 76 56.7
Radiotherapy 0.799
No 81 18.2 32 39.5 49 60.5
Yes 363 81.8 149 41 214 59
CK-19: cytokeratin-19; CMF: cyclophosphamide, methotrexate, fluorouracil; EC-T: epirubicin, cyclophosphamide, docetaxel; ER: estrogen receptor; FEC: fluorouracil,
epirubicin, cyclophosphamide; IHC: immunohistochemistry; L: lumpectomy; M: mastectomy; PR: progesterone receptor.
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Page 26 of 39Item 15. Present univariable analyses showing the relation
between the marker and outcome, with the estimated effect
(for example, hazard ratio and survival probability).
Preferably provide similar analyses for all other variables
being analyzed. For the effect of a tumor marker on a time-
to-event outcome, a Kaplan-Meier plot is recommended
Examples See Figure 3 and Table 8.
Explanation Am a r k e r ’s simple association with out-
come should be shown first, without adjustment for
other clinical or pathologic characteristics to indicate its
prognostic strength before allowance is made for other
variables.
For a binary clinical endpoint (for example, tumor
response or disease progression within one year) with a
categorical marker, authors can report the observed out-
come probabilities for each category of marker value.
Sparse categories (those with few patients) may have
been combined in the initial data analysis (see Item 10a
and Box 4). For a continuous marker it is informative to
present a summary of marker values (as in Item 13) sepa-
rately for those patients with and without the endpoint.
Alternatively, a plot of log odds ratio (or a similar mea-
sure) as a function of the continuous marker value could
be presented. A statistical test of the difference (for
example, chi-square test, t-test or test for trend) may
accompany the summary description of the association of
the marker with the outcome.
For a time-to-event outcome, the relation between a
categorical marker and outcome can be assessed by a sta-
tistical test such as the logrank test (using the test for
trend for ordered categories with more than two groups)
[160]. Additionally, a hazard ratio estimate (for example,
as derived from a Cox proportional hazards regression
model) or some other summary estimate of the
Figure 2 Frequency distribution of Steroid Receptor RNA Activator Protein (SRAP) H-scores in 372 breast tumors, showing median of
76.67 used to delineate low and high subgroups [179] (for a secondary example see Figure 1 in [29]).
Table 5 Relation between marker (serum chromogranin A) and patient characteristics [181] (note that missing data
were not indicated).
Serum CgA levels, ng/mL
Number Median Q1 to Q3 Minimum to maximum P
Subjects
Controls 50 77.4 57.7 to 99.9 28.2 to 196.3
NSCLC patients 88 70.4 37.9 to 114.6 8.7 to 723.8 0.337
Histotype
Adenocarcinoma 22 59.2 35.2 to 85.6 14.8 to 151.2
Squamous 27 80.0 41.0 to 128.6 14.7 to 386.8
Large cell 10 82.1 33.7 to 124.0 11.4 to 217.9 0.465
ECOG PS
0 16 37.7 27.2 to 68.6 8.7 to 103.1
1 59 76.3 43.6 to 119.2 13.9 to 429.7
≥2 13 102.8 55.8 to 259.4 32.1 to 723.8 0.0005
Stage
IIIB 29 44.9 29.2 to 85.6 13.9 to 259.4
IV 59 82.5 47.1 to 119.2 8.7 to 723.8 0.043
CgA: chromogranin A; ECOG PS: Eastern Cooperative Oncology Group performance status; NSCLC: non-small cell lung cancer; Q1 to Q3: interquartile range.
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Page 27 of 39association of the marker with survival time should be
presented. Precision and uncertainty of the estimates
should be indicated, for example by providing confidence
intervals. P values may also be presented. For continuous
markers, one can investigate the influence of the marker
on outcome without having to categorize the marker (see
Box 4). If any categorizations or transformations are
applied to the marker, these need to be clearly stated in
order for an association estimate to be interpretable (see
Item 11).
Similar analyses are useful for showing the relation to
outcome of all other variables being assessed. Such
Table 6 Relation between marker (E-Cadherin) and patient characteristics [182].
E-Cadherin staining index
a
Low High
Variable Number of
patients
% Number of
patients
%
Histologic type
Endometrioid
b 135 53 120 47
Clear-cell or serous papillary 24 83 5 17
FIGO grade
1 2 54 92 65 1
2 6 35 16 14 9
3 7 16 53 83 5
Vascular invasion
0 or 1 vessel 94 52 88 48
≥2 vessels 65 64 37 36
Myometrial infiltration
c,%
<50 77 51 74 49
≥50 67 66 35 34
FIGO stage
d
I or II 120 53 108 47
III or IV 39 71 16 29
aResults available in 284 patients;
bAdenosquamous and adenoacanthoma are included;
cInformation available in 253 patients (E-cadherin) and 255 patients
(beta-catenin);
dData missing in one patient.
Table 7 Relation between patient characteristics and steroid receptor status by immunocytochemistry and dextran-
coated charcoal [159]
Estrogen receptor positive Progesterone receptor positive
Parameter n (%) ICC (%) DCC (%) ICC (%) DCC (%)
Axillary node status (n = 241)
N0 120 (49.8) 88 (73.3) 98 (81.7) 83 (69.1) 93 (77.5)
N+ 121 (50.2) 75 (62.0) 89 (73.6) 75 (61.9) 94 (77.7)
Tumor size (cm) (n = 229
a)
<2 86 (37.6) 59 (68.6) 69 (80.2) 60 (69.8) 69 (80.2)
2-5 128 (55.9) 88 (68.8) 101 (78.9) 84 (65.6) 100 (78.1)
>5 15 (6.6) 8 (53.3) 9 (60.0) 8 (53.3) 9 (60.0)
Tumor histology (n = 241)
Invasive ductal 171 (71.0) 120 (70.2) 136 (79.5) 119 (69.6) 136 (79.5)
Lobular 38 (15.8) 26 (68.4) 31 (81.6) 22 (57.9) 30 (78.9)
Other
b 32 (13.2) 17 (53.1) 20 (62.5) 17 (53.1) 21 (65.6)
Tumor grade (n = 217)
c
1 + 2 142 (65.4) 106 (74.7) 118 (83.1) 104 (73.2) 119 (83.8)
3 75 (34.6) 41 (54.7) 52 (69.3) 36 (48.0) 53 (70.7)
Patient age (y) (n = 241)
≤50 63 (26.1) 26 (41.3) 42 (66.7) 45 (71.4) 54 (85.7)
>50 178 (73.9) 137 (77.0) 145 (81.5) 113 (63.5) 133 (74.7)
aNo information available on tumor size in 12 cases;
bmucinous, tubular or medullary;
cno information available on tumor grade in 24 cases. DCC: dextran-coated
charcoal; ICC: immunocytochemistry.
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tions. Results differing from expectations may point to
some problems in the study, such as biased patient selec-
tion or measurement techniques. Univariable measures
of association with outcome can sometimes be presented
conveniently along with the distributions of each variable
(see Item 13) in a single table.
For a time-to-event outcome, a plot of Kaplan-Meier
survival curves is recommended [161,162], with one
curve shown for each category of marker value (two
curves for a binary marker). The number of patients at
risk should be provided for selected time points. To plot
Kaplan-Meier estimates for continuous markers or mar-
kers with many categories, the marker values are typically
combined into a few groups. For continuous markers, the
groups are often constructed to contain equal numbers
of patients (for example, based on tertiles or quartiles) or
the groups may be defined using cutpoints established in
a previous study. Regardless of how the groups are con-
structed, the rationale should be reported. Choosing
groups based on maximizing association with outcome is
dangerous (see Item 11 and Box 4). It can also be helpful
to report estimates of survival probabilities at a few speci-
fic time points of interest along with corresponding
Figure 3 Kaplan-Meier plot for disease-free survival comparing patients with HU177 concentrations above and below the median
value. [178].
Table 8 Univariable analyses of relation of UBE2C protein and standard variables to overall survival in 92 women with
node-positive breast cancer [183].
Variable HR 95% CI P
Age 1.06 1.01 to 1.12 0.026
Histology (IDC versus others) 0.48 0.18 to 1.27 0.139
Histological size (<20 mm versus ≥20 mm) 2.97 0.68 to 12.94 0.147
SBR (I versus II versus III) 3.97 1.67 to 9.47 0.001
Positive nodes (1 versus 2 versus 3 versus >3) 1.81 1.19 to 274 0.005
Estrogen receptor (+versus -) 0.18 0.07 to 0.47 <0.001
Progesterone receptor (+versus -) 0.51 0.19 to 1.37 0.182
IHC Ki-67 (<11% versus ≥11%) 8.59 1.14 to 64.57 0.037
IHC UBE2C (<11% versus ≥11%) 7.14 1.64 to 31.11 0.009
NPI scores (1 versus 2 versus 3) 4.48 1.74 to 11.52 0.002
CI: confidence interval; IDC: infiltrating ductal carcinoma; IHC: immunohistochemistry; HR: hazard ratio; NPI: Nottingham Prognostic Index; SBR: Scarff-Bloom-
Richardson.
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category.
Univariable measures of association of the marker
with outcome and differences between Kaplan-Meier
curves might be heavily influenced by other prognostic
variables that are correlated with the marker. However,
those analyses are still useful to report as they provide a
baseline against which to compare measures of associa-
tion that are adjusted for other variables (multivariable
analysis - see Item 16). For this reason it is helpful to
present univariable regression analyses as they allow
direct comparison of the unadjusted and adjusted
hazard ratios.
Item 16. For key multivariable analyses, report estimated
effects (for example, hazard ratio) with confidence intervals
for the marker and, at least for the final model, all other
variables in the model
Examples See Tables 9 and 10.
Explanation S i n c eat u m o r ’s biological characteristics
are not controllable experimentally like treatment in a
RCT, a study examining the prognostic value of a
tumor marker is subject to the usual challenges inher-
ent in analysis of observational studies, such as adjust-
ment for the effect of potential confounding factors.
Some of these other factors are standard variables that
are generally accepted as being related to prognosis
while others might be candidate variables that are
available but have unknown prognostic significance or
uncertain relation to the marker of interest. Any of
these variables might be considered for inclusion in
multivariable models that are developed during the
course of the data analysis (see Items 12 and 17). Cer-
tain of these multivariable models are of particular
importance and the results associated with these mod-
els should be reported in more detail.
Often the multivariable data analysis involves a model
building process that begins with what we will designate
as the ‘full model’ and, after several data-dependent mod-
eling steps, may result in identification of a ‘final model’.
The full model is a model containing all the available
candidate variables (see Item 8), often depending on deci-
sions from the initial data analysis step considering miss-
ing values, distribution of the variables (for example,
collapsing of small categories) and other aspects of the
data (see Item 10a). Usually the full model contains too
many variables to be readily interpretable, but it may
serve as the starting point for variable selection, if done,
using a method such as backward elimination (see Item
10d) [66]. The final model, which is a more parsimonious
model obtained at the end of the variable selection and
modeling process, will provide estimates of adjusted
effects that are more interpretable, but the effects may
also be biased to appear stronger than they actually are
due to the variable selection process that had been used.
The ‘standardized model’ (for explanation see Item 17) is
another important multivariable model that should be
examined in prognostic studies. However, its components
are determined on the basis of clinical and pathologic
considerations rather than through data-dependent
model building, and hence it is discussed separately. The
REMARK profile (see Item 12) illustrates which analyses
were performed.
As discussed for univariable models (see Item 15), pre-
cision and significance of estimated effects should be
indicated by providing confidence intervals and P values.
At least for the final model these measures should be
provided for all variables in the model. If multivariable
models are also developed for key patient subgroups
(for example, separate models for men and women, see
Box 1), effect estimates, confidence intervals and P
values should be provided for all variables in the main
subgroup models. For additional multivariable models
that do not differ substantially from the main models
reported in detail, it may be sufficient to give effect esti-
mates with confidence intervals for the marker of inter-
est only or to summarize results in simple statements.
For example, such models might have been used in sen-
sitivity analyses in which a standard variable was elimi-
nated or in which different assumptions were used (see
Items 10g and 18).
In a review of 50 studies published in high impact can-
cer journals in 2006 to 2007, more than one multivariable
Table 9 Multivariable Cox regression analysis of relapse-
free survival in patients with primary breast cancer
showing the impact of adding the marker (PMN-E) to a
base model of recognized prognostic variables [59].
Factor HR (95% CI) P
Base model
Age and menopausal status combined 0.005
Age premenopausal
a 0.68 (0.55 to 0.85)
Age postmenopausal
a 0.96 (0.84 to 1.09)
Post- versus premenopausal 1.83 (1.27 to 2.46)
Tumor size <0.001
2 cm to 5 cm versus ≤2 cm 1.69 (1.36 to 2.10)
>5 cm versus ≤2 cm 2.31 (1.73 to 3.10)
Nodal status <0.001
N1-3 versus N0 1.66 (1.30 to 2.11)
N>3 versus N0 2.75 (2.18 to 3.47)
ER (positive versus negative)
b 0.87 (0.68 to 1.11) 0.25
PgR (positive versus negative)
b 0.76 (0.61 to 0.95) 0.02
Additions to base model
+PMN-E (high versus low)
c 1.45 (1.10 to 1.89) 0.01
+PMN-E (continuous)
d 1.06 (0.98 to 1.14) 0.13
aAge in decades for pre- and postmenopausal patients;
bPositive, ≥10 fmol/
mg protein; negative <10 ng/mg protein;
cHigh, >36.4 ng/mg protein; low,
≤36.4 ng/mg protein;
dLog-transformed variable. CI: confidence interval; ER:
estrogen receptor; PgR: progesterone receptor.
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Page 30 of 39analysis was reported in 30 of them (60%) [20]. For the
primary marker, an effect estimate with confidence inter-
val from the multivariable model was reported in 84%, but
only 66% of the papers presented effect estimates for all
variables in the final model.
Item 17. Among reported results, provide estimated effects
with confidence intervals from an analysis in which the
marker and standard prognostic variables are included,
regardless of their statistical significance
Examples ‘When all standard prognostic clinical vari-
ables were included as co-variables in a Cox proportional
hazards model, there was again no evidence that these
two markers were significantly associated with OS (HR =
0.99, 95% CI 0.79-1.25 and P = 0.9 for TS [thymidylate
synthase] and HR = 0.98, 95% CI 0.78-1.23 and P = 0.8
for p53).’ [76]
See Table 11.
Explanation For many clinical situations one can iden-
tify some standard variables that have previously been
demonstrated to have prognostic value and are generally
measured for most patients having the particular diag-
nosis. Although there may be some difference from
study to study, there may be a core group of variables
that are examined in most studies or are recommended
in clinical consensus guidelines. Typical standard vari-
ables include disease stage and its constituent elements,
such as tumor size and nodal status, and sometimes
patient demographic variables such as age or sex. Some-
times these variables are used to determine eligibility for
inclusion in a study (see Item 2). It is important to eval-
uate whether the new marker maintains some associa-
tion with clinical outcome after accounting for these
standard prognostic variables. There should be discus-
sion and explanation of how these standard variables
have been selected. Sometimes these variables may
already belong to an established multivariable score and
this should also be referenced [163].
Evaluation of a marker’s effect adjusted for standard
variables is generally accomplished by examining what
we will call the ‘standardized model’, which includes the
marker of interest as well as all of the standard vari-
ables, regardless of their statistical significance. Different
treatments may be accounted for by indicator variables
or by stratification. Irrespective of what other multivari-
able models are considered, the results of fitting this
standardized model should be explicitly reported as it
facilitates the comparison of estimated effects of the
marker across studies. This model should be clearly dis-
tinguished from other multivariable models that may
have been fit during the course of the data analysis (see
Item 12), particularly the full model and the final model
(see Item 16).
Comparison of the effect estimates from the standar-
dized model to univariable effects (see Item 15) and to
effects estimated from other key multivariable analyses
(see Item 16) will provide a clearer picture of whether
Table 10 Multivariable Cox regression models of overall survival for subgroups of size of residual postoperative tumor
[184].
No residual postoperative Residual tumor Residual tumor
tumor 1 mm to 10 mm >10 mm
Parameter HR 95% CI P HR 95% CI P HR 95% CI P
Age (10 y) 1.24 (1.11 to 1.37) <0.0001 1.12 (1.03 to 1.21) 0.0068 1.10 (1.02 to 1.18) 0.0103
ECOG 2 versus 0-1 1.78 (1.24 to 2.55) 0.0016 1.47 (1.16 to 1.87) 0.0013 1.22 (1.01 to 1.47) 0.0365
FIGO IIIC-IV versus IIB-IIIB 1.41 (1.13 to 1.75) 0.0024 1.49 (1.20 to 1.85) 0.0003 1.48 (1.16 to 1.90) 0.0019
Grading G2/3 versus G1 2.19 (1.45 to 3.30) 0.0002 1.57 (1.00 to 2.46) 0.0524 1.46 (0.99 to 2.15) 0.0569
Endometrioid versus serous 0.84 (0.61 to 1.16) 0.2867 0.95 (0.69 to 1.30) 0.7328 0.97 (0.73 to 1.29) 0.8355
Mucinous versus serous 1.97 (1.26 to 3.08) 0.0028 2.76 (1.90 to 4.02) <0.0001 2.29 (1.70 to 3.10) <0.0001
Ascites, yes versus no 1.92 (1.52 to 2.41) <0.0001 1.18 (0.96 to 1.45) 0.1178 1.31 (1.10 to 1.56) 0.0023
CI: confidence interval; HR: hazard ratio; ECOG: Eastern Cooperative Oncology Group; FIGO: Fédération Internationale de Gynécologie et d’Obstétrique.
Table 11 Prognostic values of several factors in a
multivariable analysis of overall survival for 175 patients
with ovarian carcinoma Stage III/IV [157].
Factor HR 95% CI P
Age
≤60 1.00 — 0.051
>60 1.46 1.00 to 2.13
Stage
III 1.00 — 0.33
IV 1.20 0.83 to 1.74
Grade
1 1.00 — 0.11
2 + 3 1.62 0.89 to 2.94
Residual tumor
≤5 mm 1.00 — <0.001
>5 mm 3.95 1.86 to 8.37
Ploidy
diploid 1.00 — 0.93
aneuploid 0.98 0.67 to 1.44
n = 175, number of events = 133. CI: confidence interval; HR: hazard ratio.
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that provided by existing variables. Therefore, it is
important to present the standardized model including
estimated effects for the marker and each of the stan-
dard variables and measures of their precision and sig-
nificance as indicated by confidence intervals and P
values. When the goal is to build a prognostic model
and quantify how a model with standard prognostic
variables is improved by incorporating the new marker
into the model, a measure sucha sc h a n g ei np r e d i c t i v e
accuracy can be presented [164,165] (see also Item
10d).
Item 18. If done, report results of further investigations,
such as checking assumptions, sensitivity analyses and
internal validation
Examples ‘Estimated effects were similar in the model
without stratification (data not shown). In a sensitivity
analysis on the complete case population (128 patients,
29 deaths), number of arteries and angioinvasion were
still the strongest prognostic factors.’ [166]
‘No significant deviation from the proportional-hazard
assumption could be found by evaluating an interaction
term of the change variables and the logarithm of time.
Furthermore, the interaction between the change during
the first and the change during the second month was
not significant.’ [167]
‘A more detailed investigation with the multivariable
fractional polynomial approach did not reveal any strong
indication of a nonlinear effect and selected the same
variables.’ [136]
Explanation R e s u l t so fm a n yp r o g n o s t i cs t u d i e sr e l yo n
the validity of the statistical models used in the analysis,
and inherent in any model are certain assumptions (for
example, proportional hazards, linear effects of covariates
and missing data mechanisms). Prognostic analysis
results will have greater credibility if arguments can be
made that the modeling assumptions are likely to be
justifiable or that the results are not unduly sensitive to
certain assumptions. The report should mention the
results obtained from any additional analyses that were
performed or diagnostic plots that were examined for the
purpose of checking assumptions or demonstrating
robustness of results (see Item 10g and Box 4). It will
often be impractical or unnecessary to present detailed
findings of these assessments, but a brief summary of the
findings should be stated. For example, a statement that
a smoothed plot of martingale residuals against a covari-
ate exhibited a linear trend would provide support for
inclusion of the covariate as a linear term in a Cox
proportional hazards regression model; a statement that
covariates were checked for possible time-varying effects
in a Cox regression model but no significant effect
seemed to be present would provide support for the
assumption of proportional hazards. Results of
assessments for differential marker effects across sub-
groups or other types of interactions should be reported
(see Box 1). Stability analyses, for example, by using the
bootstrap [147,168], and conducting assessments includ-
ing, but not limited to, those mentioned above (see Item
10g) will provide supporting evidence for the appropri-
ateness of final model(s) that provide the basis for the
conclusions of the study [99,133].
In some situations, modeling assumptions cannot be
empirically verified, and the only recourse may be to
demonstrate by sensitivity analyses whether a reasonable
range of alternative assumptions still lead to similar con-
clusions as those reported for the main analysis. For exam-
ple, this problem is routinely encountered when applying
missing data imputation methods [128,130] (see also Box
2). Because true missing data mechanisms are usually
unknown, it is recommended that results of any alternative
analyses (including complete case analysis) performed
under different assumptions about the missing data
mechanism (missing completely at random, missing at
random or missing not at random) be reported so that the
amount the results would change can be assessed.
If either internal validation analyses or external valida-
tion studies have been performed (see Item 10h), the
results of those analyses should be described, regardless
of the findings. Successful validations greatly improve
the chances that the study findings are real.
Discussion
Item 19. Interpret the results in the context of the pre-
specified hypotheses and other relevant studies; include a
discussion of the limitations of the study
Examples ‘We evaluated the prognostic significance of
three VEGF SNPs in a large cohort of patients with eso-
phageal cancer. In multivariate analysis, we showed that
the heterozygous and homozygous variant genotype of
VEGF 936C/T conferred an improved OS compared
with the homozygous wild-type genotype ... Although
this is the first study to evaluate VEGF SNPs in esopha-
geal cancer, two prior gastric cancer studies reported
conflicting results ... There are limitations to this study.
Although others have correlated these VEGF SNPs with
plasma VEGF levels, due to the lack of available tissue
samples, we were unable to correlate VEGF genotype
with VEGF mRNA or protein expression within tumors
... Secondly, the sample size of 361 is very large for eso-
phageal cancer but is only average for all studies evalu-
ating VEGF polymorphisms and cancer outcomes
(median sample size, 413; range, 100-1193). Finally, we
used a candidate polymorphism approach, which allows
us to compare with studies of other disease sites and
focuses on functional variants, but therefore will not
evaluate the entirety of polymorphic variation across
this gene.’ [169]
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ciated with larger tumors, younger patient age, and gen-
erally more aggressive breast cancer. These findings are
consistent with several other studies that have shown
COX-2 expression to be associated with more aggressive
disease. Studies evaluating COX-2 expression as it relates
to breast cancer aggressiveness and outcome are sum-
marized in Table 4.’ [170]
Explanation The discussion is the appropriate section
for authors to interpret the data and suggest further
research that might be needed. The section should begin
by briefly restating the purpose of the study and recalling
any pre-specified hypotheses. A simple summary of the
major findings should follow. This allows the reader to
assess if the study met its goals and to evaluate the evi-
dence. A clear distinction should be made between con-
clusions based on pre-specified hypotheses and
hypotheses suggested during the course of the data
analysis.
The authors should critically evaluate the reported
results. This evaluation should include an acknowledg-
ment of any biases or inconsistencies in the data, limita-
tions of the assay methods or limitations of the design
or data analysis methods. For example, the study may
have been underpowered, it may have been limited to
only tumors of sufficiently large size, the assay might be
lacking in reproducibility, important standard variables
may have not been available (for example, tumor grade
in breast cancer) and there may have been a large
amount of missing data requiring certain assumptions
to be made in the analyses. If there are strong biologi-
cally plausible subgroup effects, the discussion should
review how the prognostic value of the marker varies
across those subgroups. A thorough and open discussion
will maximize the value of the study results to the
broader community, regardless of whether the study
results are as the investigators had hoped at the initia-
tion of their study. This discussion should include the
authors’ assessment of whether the results of the study
are generalizable to other populations not studied in the
current report. Any unexpected findings should be iden-
tified. Even disappointing or unexpected findings can
yield important insights.
Following the summary, there should be a discussion
of how the results from the study integrate into the
existing body of evidence. It is helpful to include an
explanation for the choice of references cited (for exam-
ple, only large studies or only studies in a similar patient
population) to allow the reader to evaluate whether
selective citation of references has influenced the inter-
pretation of the results. If a systematic review was con-
ducted, it should be described. (If the review was
performed prior to initiation of the study, its description
may fit better in Item 1.) Authors should comment on
whether the results are consistent with, or differ from,
the general tendency in previous studies and offer
potential explanations for differences.
Item 20. Discuss implications for future research and
clinical value
Example ‘The association of SMAD4 gene inactivation
with poorer prognosis and an increased propensity to
metastasize has direct clinical implications. Some
patients with pancreatic cancer have ‘’borderline’’ resect-
able tumors - they have resectable pancreatic head can-
cers that are at high risk for a margin-positive resection.
Whereas further work is needed, our results, combined
with those previously reported in the literature, suggest
that patients with borderline resectable pancreatic can-
cers and SMAD4 gene inactivation might be spared the
risk of surgery because their cancer is more likely to
metastasize, whereas patients with borderline resectable
pancreatic cancers and intact SMAD4 may benefit from
the local control provided by neoadjuvant therapy and
surgical resection.’ [171]
Explanation The rationale for studying any marker,
prognostic or otherwise, is to gain relevant information
about the biology of the disease, to find new tools to aid
in clinical decision-making or to develop new treatments.
Observation of a statistically significant association
between a marker and an outcome may be encouraging,
but in the long term the difference in outcome should
have clinically important implications for patient care. If
a prognostic marker does not provide added value to
existing prognostic information, it may nevertheless be
useful if it can be assessed more easily, at lower cost or
measured more reproducibly than markers currently
used to provide clinically meaningful information.
In some cases, the results of a study will suggest that a
marker has some promise for clinical value, but a firm
conclusion cannot be drawn due to insufficient informa-
tion. It is helpful in the discussion of future research
plans to specifically identify information that is still lack-
ing or inadequate. For example, further studies might
need to be conducted in expanded patient populations
or different patient subsets. Contemporary patient popu-
lations diagnosed and staged using updated methods
and receiving more modern therapies and supportive
care might need to be studied. Further research studies
may be required to resolve differences in the perfor-
mance of the marker noted in the literature. The assay
m e t h o dm i g h tn e e dr e f i n e m e n tt oi m p r o v ei t sr o b u s t -
ness and accuracy before it is ready to be used in rou-
tine clinical settings.
Ultimately, the goal of the research is to provide a tool
of clinically meaningful value to improve patient out-
comes. The discussion needs to provide a clear under-
standing of what the current study has achieved toward
that goal and what steps remain.
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Physicians seek information about tumor markers to
inform therapeutic decisions for individual patients. The
availability of a marker that can distinguish subsets of
patients may also influence the design of clinical trials.
In order for information about the utility of tumor mar-
kers to be appropriately evaluated, the methods used to
study the markers and the results generated must be
fully reported. The REMARK recommendations were
designed to help authors ensure that reports of their
tumor marker studies contain the information that read-
ers need. Good reporting reveals the strengths and
weaknesses of a study and facilitates sound interpreta-
tion and application of study results. The REMARK
recommendations may also aid in planning new studies,
and may be helpful for peer reviewers and editors in
their evaluation of manuscripts.
It was always our intention to supplement the check-
list publication [1-7] with a long explanatory paper, as
has been done for CONSORT, STROBE and the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement, for example
[9-11,172]. Following the same model as those articles,
in this paper we have provided extensive discussion of
each item in the REMARK checklist, providing the
rationale and including illustrative examples of good
reporting. Where possible we have referred to relevant
empirical evidence from reviews of publications. We
have also included several boxes to provide additional
discussion of some key aspects of prognostic studies.
Although we have primarily focused on studies of sin-
gle prognostic markers, most of the recommendations
apply equally to other types of prognostic studies,
including studies of multiple markers, studies to predict
response to treatment and studies to develop prognostic
models. The REMARK recommendations offer criteria
against which to judge the completeness of reporting of
marker studies. We hope that improvements will be
seen over time, but as yet reviews have shown that
incomplete reporting is regrettably common
[15,18,20,21,173]. We believe that the REMARK recom-
mendations should be useful in specialties other than
cancer, and there are already examples that this is so
[21,174-176].
REMARK is not intended to dictate standards for the
quality of research and it should not be used as such.
H o w e v e r ,i tc a nb eau s e f u lt o o lt oh e l pa s s e m b l et h e
information needed in order to assess the quality and rele-
vance of research.
Reporting recommendations should change as necessary
to reflect new empirical evidence and changes in our
understanding of which aspects of research are important.
We intend to monitor the literature for new evidence and
critical comments in the expectation that the checklist will
be updated in the future.
Several cancer journals ask authors to follow the
REMARK recommendations in their instructions to
authors; we encourage more journals to follow this
example. Up-to-date information on REMARK and
numerous other reporting guidelines can be found on
the website of the EQUATOR Network http://www.
equator-network.org.
Additional material
Additional file 1: REMARK reporting template. REMARK checklist for
authors to complete to accompany a journal submission of a report of a
study investigating a prognostic marker.
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